<pmc-articleset>
  <article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4">
    <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
      <restricted-by>pmc</restricted-by>
    </processing-meta>
    <front>
      <journal-meta>
        <journal-id journal-id-type="nlm-ta">Front Oncol</journal-id>
        <journal-id journal-id-type="iso-abbrev">Front Oncol</journal-id>
        <journal-id journal-id-type="pmc-domain-id">1755</journal-id>
        <journal-id journal-id-type="pmc-domain">frontonco</journal-id>
        <journal-id journal-id-type="publisher-id">Front. Oncol.</journal-id>
        <journal-title-group>
          <journal-title>Frontiers in Oncology</journal-title>
        </journal-title-group>
        <issn pub-type="epub">2234-943X</issn>
        <publisher>
          <publisher-name>Frontiers Media SA</publisher-name>
        </publisher>
      </journal-meta>
      <article-meta>
        <article-id pub-id-type="pmcid">PMC9379253</article-id>
        <article-id pub-id-type="pmcid-ver">PMC9379253.1</article-id>
        <article-id pub-id-type="pmcaid">9379253</article-id>
        <article-id pub-id-type="pmcaiid">9379253</article-id>
        <article-id pub-id-type="pmid">35982973</article-id>
        <article-id pub-id-type="doi">10.3389/fonc.2022.919118</article-id>
        <article-version article-version-type="pmc-version">1</article-version>
        <article-categories>
          <subj-group subj-group-type="heading">
            <subject>Oncology</subject>
            <subj-group>
              <subject>Original Research</subject>
            </subj-group>
          </subj-group>
        </article-categories>
        <title-group>
          <article-title>Whole genome analysis reveals the genomic complexity in metastatic cutaneous squamous cell carcinoma</article-title>
        </title-group>
        <contrib-group>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Thind</surname>
              <given-names initials="AS">Amarinder Singh</given-names>
            </name>
            <xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref>
            <xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref>
            <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/1234767"/>
          </contrib>
          <contrib contrib-type="author" corresp="yes">
            <name name-style="western">
              <surname>Ashford</surname>
              <given-names initials="B">Bruce</given-names>
            </name>
            <xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref>
            <xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref>
            <xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref>
            <xref rid="fn001" ref-type="author-notes">
<sup>*</sup>
</xref>
            <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/1456331"/>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Strbenac</surname>
              <given-names initials="D">Dario</given-names>
            </name>
            <xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref>
            <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/1329241"/>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Mitchell</surname>
              <given-names initials="J">Jenny</given-names>
            </name>
            <xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref>
            <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/1648387"/>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Lee</surname>
              <given-names initials="J">Jenny</given-names>
            </name>
            <xref rid="aff5" ref-type="aff">
<sup>5</sup>
</xref>
            <xref rid="aff6" ref-type="aff">
<sup>6</sup>
</xref>
            <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/1545629"/>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Mueller</surname>
              <given-names initials="SA">Simon A.</given-names>
            </name>
            <xref rid="aff5" ref-type="aff">
<sup>5</sup>
</xref>
            <xref rid="aff7" ref-type="aff">
<sup>7</sup>
</xref>
            <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/1735600"/>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Minaei</surname>
              <given-names initials="E">Elahe</given-names>
            </name>
            <xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref>
            <xref rid="aff8" ref-type="aff">
<sup>8</sup>
</xref>
            <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/1649373"/>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Perry</surname>
              <given-names initials="JR">Jay R.</given-names>
            </name>
            <xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref>
            <xref rid="aff8" ref-type="aff">
<sup>8</sup>
</xref>
            <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/1648694"/>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Ch’ng</surname>
              <given-names initials="S">Sydney</given-names>
            </name>
            <xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref>
            <xref rid="aff5" ref-type="aff">
<sup>5</sup>
</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Iyer</surname>
              <given-names initials="NG">N. Gopalakrishna</given-names>
            </name>
            <xref rid="aff9" ref-type="aff">
<sup>9</sup>
</xref>
            <xref rid="aff10" ref-type="aff">
<sup>10</sup>
</xref>
            <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/1724721"/>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Clark</surname>
              <given-names initials="JR">Jonathan R.</given-names>
            </name>
            <xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref>
            <xref rid="aff5" ref-type="aff">
<sup>5</sup>
</xref>
            <xref rid="aff11" ref-type="aff">
<sup>11</sup>
</xref>
            <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/1734007"/>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Gupta</surname>
              <given-names initials="R">Ruta</given-names>
            </name>
            <xref rid="aff12" ref-type="aff">
<sup>12</sup>
</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Ranson</surname>
              <given-names initials="M">Marie</given-names>
            </name>
            <xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref>
            <xref rid="aff8" ref-type="aff">
<sup>8</sup>
</xref>
            <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/1573766"/>
          </contrib>
        </contrib-group>
        <aff id="aff1">
<sup>1</sup>
<institution>School of Medicine, University of Wollongong</institution>, <addr-line>Wollongong, NSW</addr-line>, <country>Australia</country>
</aff>
        <aff id="aff2">
<sup>2</sup>
<institution>Illawarra Health and Medical Research Institute</institution>, <addr-line>Wollongong, NSW</addr-line>, <country>Australia</country>
</aff>
        <aff id="aff3">
<sup>3</sup>
<institution>Illawarra Shoalhaven Local Health District</institution>, <addr-line>Wollongong, NSW</addr-line>, <country>Australia</country>
</aff>
        <aff id="aff4">
<sup>4</sup>
<institution>Sydney Medical School, Faculty of Medicine and Health, The University of Sydney</institution>, <addr-line>NSW</addr-line>, <country>Australia</country>
</aff>
        <aff id="aff5">
<sup>5</sup>
<institution>Sydney Head and Neck Cancer Institute, Chris O’Brien Lifehouse</institution>, <addr-line>Sydney, NSW</addr-line>, <country>Australia</country>
</aff>
        <aff id="aff6">
<sup>6</sup>
<institution>Department of Clinical Medicine, Macquarie University</institution>, <addr-line>Sydney, NSW</addr-line>, <country>Australia</country>
</aff>
        <aff id="aff7">
<sup>7</sup>
<institution>Department of Otorhinolaryngology, Head and Neck Surgery, Zurich University Hospital and University of Zurich</institution>, <addr-line>Zurich</addr-line>, <country>Switzerland</country>
</aff>
        <aff id="aff8">
<sup>8</sup>
<institution>School of Chemistry and Molecular Bioscience, University of Wollongong</institution>, <addr-line>Wollongong, NSW</addr-line>, <country>Australia</country>
</aff>
        <aff id="aff9">
<sup>9</sup>
<institution>Department of Head and Neck Surgery, National Cancer Center</institution>, <addr-line>Singapore</addr-line>, <country>Singapore</country>
</aff>
        <aff id="aff10">
<sup>10</sup>
<institution>Duke-NUS Medical School</institution>, <addr-line>Singapore</addr-line>, <country>Singapore</country>
</aff>
        <aff id="aff11">
<sup>11</sup>
<institution>Royal Prince Alfred Institute of Academic Surgery, Sydney Local Health District</institution>, <addr-line>Sydney, NSW</addr-line>, <country>Australia</country>
</aff>
        <aff id="aff12">
<sup>12</sup>
<institution>Anatomical Pathology, Royal Prince Alfred Hospital</institution>, <addr-line>Sydney, NSW</addr-line>, <country>Australia</country>
</aff>
        <author-notes>
          <fn fn-type="edited-by">
            <p>Edited by: Gagan Chhabra, University of Wisconsin-Madison, United States</p>
          </fn>
          <fn fn-type="edited-by">
            <p>Reviewed by: Takamichi Ito, Kyushu University, Japan; Shengqin Su, Shanghai Hengrui Pharmaceutical Co., Ltd., China</p>
          </fn>
          <corresp id="fn001">*Correspondence: Bruce Ashford, <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mailto:bruceash@uow.edu.au">bruceash@uow.edu.au</email></corresp>
          <fn fn-type="other" id="fn002">
            <p>This article was submitted to Skin Cancer, a section of the journal Frontiers in Oncology</p>
          </fn>
        </author-notes>
        <pub-date pub-type="epub">
          <day>02</day>
          <month>8</month>
          <year>2022</year>
        </pub-date>
        <pub-date pub-type="collection">
          <year>2022</year>
        </pub-date>
        <volume>12</volume>
        <issue-id pub-id-type="pmc-issue-id">400062</issue-id>
        <elocation-id>919118</elocation-id>
        <history>
          <date date-type="received">
            <day>13</day>
            <month>4</month>
            <year>2022</year>
          </date>
          <date date-type="accepted">
            <day>27</day>
            <month>6</month>
            <year>2022</year>
          </date>
        </history>
        <pub-history>
          <event event-type="pmc-release">
            <date>
              <day>01</day>
              <month>01</month>
              <year>2022</year>
            </date>
          </event>
          <event event-type="pmc-live">
            <date>
              <day>17</day>
              <month>08</month>
              <year>2022</year>
            </date>
          </event>
          <event event-type="pmc-last-change">
            <date iso-8601-date="2022-08-19 15:17:36.573">
              <day>19</day>
              <month>08</month>
              <year>2022</year>
            </date>
          </event>
        </pub-history>
        <permissions>
          <copyright-statement>Copyright © 2022 Thind, Ashford, Strbenac, Mitchell, Lee, Mueller, Minaei, Perry, Ch’ng, Iyer, Clark, Gupta and Ranson</copyright-statement>
          <copyright-year>2022</copyright-year>
          <copyright-holder>Thind, Ashford, Strbenac, Mitchell, Lee, Mueller, Minaei, Perry, Ch’ng, Iyer, Clark, Gupta and Ranson</copyright-holder>
          <license>
            <ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
            <license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p>
          </license>
        </permissions>
        <self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="fonc-12-919118.pdf"/>
        <abstract>
          <p>Metastatic cutaneous squamous cell carcinoma (CSCC) is a highly morbid disease requiring radical surgery and adjuvant therapy, which is associated with a poor prognosis. Yet, compared to other advanced malignancies, relatively little is known of the genomic landscape of metastatic CSCC. We have previously reported the mutational signatures and mutational patterns of CCCTC-binding factor (CTCF) regions in metastatic CSCC. However, many other genomic components (indel signatures, non-coding drivers, and structural variants) of metastatic CSCC have not been reported. To this end, we performed whole genome sequencing on lymph node metastases and blood DNA from 25 CSCC patients with regional metastases of the head and neck. We designed a multifaceted computational analysis at the whole genome level to provide a more comprehensive perspective of the genomic landscape of metastatic CSCC. In the non-coding genome, 3′ untranslated region (3′UTR) regions of <italic toggle="yes">EVC</italic> (48% of specimens), <italic toggle="yes">PPP1R1A</italic> (48% of specimens), and <italic toggle="yes">ABCA4</italic> (20% of specimens) along with the tumor-suppressing long non-coding RNA (lncRNA) LINC01003 (64% of specimens) were significantly functionally altered (Q-value &lt; 0.05) and represent potential non-coding biomarkers of CSCC. Recurrent copy number loss in the tumor suppressor gene <italic toggle="yes">PTPRD</italic> was observed. Gene amplification was much less frequent, and few genes were recurrently amplified. Single nucleotide variants driver analyses from three tools confirmed <italic toggle="yes">TP53</italic> and <italic toggle="yes">CDKN2A</italic> as recurrently mutated genes but also identified <italic toggle="yes">C9</italic> as a potential novel driver in this disease. Furthermore, indel signature analysis highlighted the dominance of ID signature 13 (ID13) followed by ID8 and ID9. ID9 has previously been shown to have no association with skin melanoma, unlike ID13 and ID8, suggesting a novel pattern of indel variation in metastatic CSCC. The enrichment analysis of various genetically altered candidates shows enrichment of “TGF-beta regulation of extracellular matrix” and “cell cycle G1 to S check points.” These enriched terms are associated with genetic instability, cell proliferation, and migration as mechanisms of genomic drivers of metastatic CSCC.</p>
        </abstract>
        <kwd-group>
          <kwd>CSCC</kwd>
          <kwd>cutaneous</kwd>
          <kwd>squamous cell carcinoma</kwd>
          <kwd>metastases</kwd>
          <kwd>UTR - Untranslated regions</kwd>
          <kwd>noncoding</kwd>
          <kwd>mutations</kwd>
          <kwd>whole genome sequencing</kwd>
        </kwd-group>
        <counts>
          <fig-count count="7"/>
          <table-count count="3"/>
          <equation-count count="0"/>
          <ref-count count="94"/>
          <page-count count="17"/>
          <word-count count="7487"/>
        </counts>
        <custom-meta-group>
          <custom-meta>
            <meta-name>pmc-status-qastatus</meta-name>
            <meta-value>0</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-status-live</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-status-embargo</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-status-released</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-open-access</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-olf</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-manuscript</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-legally-suppressed</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-has-pdf</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-has-supplement</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-pdf-only</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-suppress-copyright</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-is-real-version</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-is-scanned-article</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-preprint</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-in-epmc</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
        </custom-meta-group>
      </article-meta>
    </front>
    <body>
      <sec sec-type="intro" id="s1">
        <title>Introduction</title>
        <p>Cutaneous squamous cell carcinoma (CSCC) is the second most common malignancy, after basal cell carcinoma (BCC), affecting up to 1,000,000 people in the United States annually (<xref rid="B1" ref-type="bibr">1</xref>). In time, and as a result of the aging population and changing ratios of BCC/CSCC, the mortality rate of CSCC is likely to exceed that of melanoma (<xref rid="B2" ref-type="bibr">2</xref>). Although primary CSCC is common, metastasis only occurs in 2%–5% of CSCC (<xref rid="B3" ref-type="bibr">3</xref>–<xref rid="B5" ref-type="bibr">5</xref>). CSCCs arising in the head and neck generally show a predictable pattern of spread, predominantly metastasizing to the intraparotid, level II (upper jugular), and perifacial lymph nodes (<xref rid="B4" ref-type="bibr">4</xref>). CSCCs that have metastasized to regional lymph nodes are associated with a worse prognosis (<xref rid="B6" ref-type="bibr">6</xref>), with modest progress made in the management of regionally advanced disease over the last 15 years. Most patients with regional metastases from CSCC of the head and neck are managed with a multimodality approach, which usually involves surgery (parotidectomy and neck dissection) and adjuvant external beam radiotherapy depending on the site and stage at the time of diagnosis (<xref rid="B7" ref-type="bibr">7</xref>–<xref rid="B9" ref-type="bibr">9</xref>). More recently immunotherapy has attracted great interest as a potential alternative for unresectable or distant metastatic disease (<xref rid="B10" ref-type="bibr">10</xref>, <xref rid="B11" ref-type="bibr">11</xref>).</p>
        <p>Despite the very high incidence, relatively little is known regarding the genomic landscape of metastatic CSCC. We have previously described the genomic mutational burden, mutational signatures, and mutations in CCCTC-binding factor regions using whole genome sequencing (WGS) data from 15 CSCC metastases (<xref rid="B12" ref-type="bibr">12</xref>) and associated cell lines (<xref rid="B13" ref-type="bibr">13</xref>). However, the majority of studies to date has reported on somatic variation in primary CSCC (<xref rid="B14" ref-type="bibr">14</xref>–<xref rid="B17" ref-type="bibr">17</xref>) and/or CSCC metastases (<xref rid="B17" ref-type="bibr">17</xref>–<xref rid="B21" ref-type="bibr">21</xref>), using whole exome sequencing (WES) and/or targeted next generation sequencing, which by definition focuses on the coding genome. Thus, the extent of analysis of non-coding (including regulatory) regions of the genome is limited and varies across studies. Pickering et al. (<xref rid="B21" ref-type="bibr">21</xref>), the only study employing WES and incorporating 32 primary and only seven metastatic samples, did not include regulatory or non-exome regions analysis. Both Li et al. (<xref rid="B19" ref-type="bibr">19</xref>) [29 lymph node metastatic formalin fixed paraffin embedded (FFPE) samples] and Zehir et al. (<xref rid="B18" ref-type="bibr">18</xref>) (MSK-IMPACT) (28 primary and 27 metastatic FFPE samples) used targeted next-generation sequencing (NGS), with limited non-coding analysis. Zehir et al. (<xref rid="B18" ref-type="bibr">18</xref>) specifically included the <italic toggle="yes">TERT</italic> promoter in their targeted panels but otherwise included no regulatory elements. Li et al. (<xref rid="B19" ref-type="bibr">19</xref>) similarly did not include regulatory or non-coding variant analysis. Yilmaz et al. (<xref rid="B17" ref-type="bibr">17</xref>) performed WES and/or targeted NGS on 18 metastatic and 10 primary FFPE CSCC samples and reported coding gene drivers based purely on mutational frequencies, without adjusting for gene length or covariates. Additional functional driver predictions analysis would be required to confidently call genes as drivers (<xref rid="B22" ref-type="bibr">22</xref>). Furthermore, FFPE processing has well-known impacts on the quality of DNA for sequencing analyses (<xref rid="B23" ref-type="bibr">23</xref>), and it is important to note that for most of the metastatic studies, FFPE samples were collected. Furthermore, none of these studies addressed variation in either 5′ or 3′ untranslated regions (UTRs) or other non-coding elements such as promoters (other than <italic toggle="yes">TERT</italic> promoter) or long non-coding RNAs (lncRNAs). Sequence variants occurring within these functional non-coding elements are important, as they have the potential to alter gene expression. For example, lncRNAs are thought to influence the expression of proteins by pre- and post-translational influences on DNA/RNA and proteins, chromatin function, miRNA activity, and signaling pathways by an array of mechanisms (<xref rid="B24" ref-type="bibr">24</xref>, <xref rid="B25" ref-type="bibr">25</xref>). 3′UTRs regulate crucial aspects of post-transcriptional gene regulation (<xref rid="B26" ref-type="bibr">26</xref>). Mutations in these regions can deregulate gene expression by disrupting miRNA–mRNA interactions, in which both tumor suppressor genes and oncogenes can drive cancer progression (<xref rid="B27" ref-type="bibr">27</xref>, <xref rid="B28" ref-type="bibr">28</xref>). This variation in the so-called <italic toggle="yes">cis-elements</italic> can also impact gene expression by altering translation initiation in cancer (<xref rid="B29" ref-type="bibr">29</xref>).</p>
        <p>Given the shortcomings associated with WES and NGS analyses of complex genomes, in the current report we have performed WGS on 25 metastatic CSCC samples and applied a detailed, multifaceted computational analysis at the whole genome level to provide a comprehensive understanding of the genomic landscape of metastatic CSCC. This included processing of WGS data for somatic variations in both coding and non-coding regions and indel signatures, apart from structural variants and copy number alterations analyses. For non-coding genomic regions, we have focused on UTRs, lncRNA, and promoter regions, as these represent non-coding regions that are most accessible to interrogation in high mutational burden tumors using currently available tools.</p>
      </sec>
      <sec sec-type="materials|methods" id="s2">
        <title>Materials and methods</title>
        <sec id="s2_1">
          <title>Study population, sample collection, and processing</title>
          <p>This study was undertaken with Institutional Human Research Ethics approval (UOW/ISLHD HREC14/397). Thirty-two patients with resectable metastatic CSCC were identified by the treating surgeons preoperatively. Clinicopathological data including age, sex, extent of nodal metastases, histology, and immunosuppression status were collected. In addition to whole blood (for germline DNA), sections of fresh tumor from nodal metastases were collected during surgery and immediately snap frozen. These sections were used for DNA extraction (Qiagen AllPrep, Qiagen, Hilden, Germany) and for cellularity estimates. Only samples with &gt;30% tumor (range, 35%–95%) proceeded to DNA quality control (QC). QC comprised spectrophotometry (Nanodrop 2000 Thermo Fisher Scientific Inc.), gel electrophoresis, and single nucleotide polymorphism (SNP) array. Of the 32 samples sequenced, 25 passed QC (96% from men) (<xref rid="T1" ref-type="table"><bold>Table 1</bold></xref>). The remaining seven samples had insufficient clonal tumor content [median variant reads ≤ 5 or median variant allele frequency (VAF) &lt; 0.1] or had an extreme GC bias as determined by PURity and PLoidy Estimator (PURPLE) (<xref rid="B30" ref-type="bibr">30</xref>). Briefly, if more than 220 copy number segments were unsupported by a corresponding structural variants at either end, the sample was flagged as fail-segment. The mean sequencing coverage of the 25 samples was 94.56× (range, 64–143) for tumor and 41.08× (range, 30–56) for blood.</p>
          <table-wrap position="float" id="T1" orientation="portrait">
            <label>Table 1</label>
            <caption>
              <p>Clinicopathological data of the cohort of 25 patients with CSCC lymph node metastases.</p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th valign="top" align="left" rowspan="1" colspan="1">Sample</th>
                  <th valign="top" align="center" rowspan="1" colspan="1">Age (years)</th>
                  <th valign="top" align="center" rowspan="1" colspan="1">Sex</th>
                  <th valign="top" align="center" rowspan="1" colspan="1">Primary location</th>
                  <th valign="top" align="center" rowspan="1" colspan="1">Metastasis location </th>
                  <th valign="top" align="center" rowspan="1" colspan="1">Nodal stage<xref rid="fn1" ref-type="fn">
<sup>1</sup>
</xref>
</th>
                  <th valign="top" align="center" rowspan="1" colspan="1">Lymph node ratio<xref rid="fn2" ref-type="fn">
<sup>2</sup>
</xref>
</th>
                  <th valign="top" align="center" rowspan="1" colspan="1">Extracapsular spread</th>
                  <th valign="top" align="center" rowspan="1" colspan="1">Grade<xref rid="fn3" ref-type="fn">
<sup>3</sup>
</xref>
</th>
                  <th valign="top" align="center" rowspan="1" colspan="1">Immuno-suppressive treatment</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1">CSCC_0001</td>
                  <td valign="top" align="center" style="background-color: " rowspan="1" colspan="1">30</td>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1">male</td>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1">left lip</td>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1">left neck</td>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1">N3b</td>
                  <td valign="top" align="center" style="background-color: " rowspan="1" colspan="1">3/27</td>
                  <td valign="top" align="center" style="background-color: " rowspan="1" colspan="1">yes</td>
                  <td valign="top" align="center" style="background-color: " rowspan="1" colspan="1">1</td>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1">no</td>
                </tr>
                <tr>
                  <td valign="top" align="left" rowspan="1" colspan="1">CSCC_0002</td>
                  <td valign="top" align="center" rowspan="1" colspan="1">78</td>
                  <td valign="top" align="left" rowspan="1" colspan="1">male</td>
                  <td valign="top" align="left" rowspan="1" colspan="1">right ear</td>
                  <td valign="top" align="left" rowspan="1" colspan="1">right parotid</td>
                  <td valign="top" align="left" rowspan="1" colspan="1">N3b</td>
                  <td valign="top" align="center" rowspan="1" colspan="1">2/52</td>
                  <td valign="top" align="center" rowspan="1" colspan="1">yes</td>
                  <td valign="top" align="center" rowspan="1" colspan="1">3</td>
                  <td valign="top" align="left" rowspan="1" colspan="1">no</td>
                </tr>
                <tr>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1">CSCC_0003</td>
                  <td valign="top" align="center" style="background-color: " rowspan="1" colspan="1">74</td>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1">male</td>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1">unknown</td>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1">right parotid</td>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1">N3b</td>
                  <td valign="top" align="center" style="background-color: " rowspan="1" colspan="1">2/42</td>
                  <td valign="top" align="center" style="background-color: " rowspan="1" colspan="1">yes</td>
                  <td valign="top" align="center" style="background-color: " rowspan="1" colspan="1">3</td>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1">no</td>
                </tr>
                <tr>
                  <td valign="top" align="left" rowspan="1" colspan="1">CSCC_0004</td>
                  <td valign="top" align="center" rowspan="1" colspan="1">64</td>
                  <td valign="top" align="left" rowspan="1" colspan="1">male</td>
                  <td valign="top" align="left" rowspan="1" colspan="1">bilateral lip</td>
                  <td valign="top" align="left" rowspan="1" colspan="1">bilateral neck</td>
                  <td valign="top" align="left" rowspan="1" colspan="1">N2c</td>
                  <td valign="top" align="center" rowspan="1" colspan="1">3/55</td>
                  <td valign="top" align="center" rowspan="1" colspan="1">no</td>
                  <td valign="top" align="center" rowspan="1" colspan="1">2</td>
                  <td valign="top" align="left" rowspan="1" colspan="1">no</td>
                </tr>
                <tr>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1">CSCC_0005</td>
                  <td valign="top" align="center" style="background-color: " rowspan="1" colspan="1">78</td>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1">male</td>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1">left forehead</td>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1">left parotid</td>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1">N2a</td>
                  <td valign="top" align="center" style="background-color: " rowspan="1" colspan="1">4/4</td>
                  <td valign="top" align="center" style="background-color: " rowspan="1" colspan="1">Not stated</td>
                  <td valign="top" align="center" style="background-color: " rowspan="1" colspan="1">3</td>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1">no</td>
                </tr>
                <tr>
                  <td valign="top" align="left" rowspan="1" colspan="1">CSCC_0006</td>
                  <td valign="top" align="center" rowspan="1" colspan="1">69</td>
                  <td valign="top" align="left" rowspan="1" colspan="1">male</td>
                  <td valign="top" align="left" rowspan="1" colspan="1">left cheek</td>
                  <td valign="top" align="left" rowspan="1" colspan="1">left neck</td>
                  <td valign="top" align="left" rowspan="1" colspan="1">N3b</td>
                  <td valign="top" align="center" rowspan="1" colspan="1">2/42</td>
                  <td valign="top" align="center" rowspan="1" colspan="1">yes</td>
                  <td valign="top" align="center" rowspan="1" colspan="1">3</td>
                  <td valign="top" align="left" rowspan="1" colspan="1">azathioprine</td>
                </tr>
                <tr>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1">CSCC_0007</td>
                  <td valign="top" align="center" style="background-color: " rowspan="1" colspan="1">87</td>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1">male</td>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1">unknown</td>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1">left neck</td>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1">N2b</td>
                  <td valign="top" align="center" style="background-color: " rowspan="1" colspan="1">1/16</td>
                  <td valign="top" align="center" style="background-color: " rowspan="1" colspan="1">no</td>
                  <td valign="top" align="center" style="background-color: " rowspan="1" colspan="1">3</td>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1">no</td>
                </tr>
                <tr>
                  <td valign="top" align="left" rowspan="1" colspan="1">CSCC_0009</td>
                  <td valign="top" align="center" rowspan="1" colspan="1">66</td>
                  <td valign="top" align="left" rowspan="1" colspan="1">male</td>
                  <td valign="top" align="left" rowspan="1" colspan="1">bilateral forehead</td>
                  <td valign="top" align="left" rowspan="1" colspan="1">right neck</td>
                  <td valign="top" align="left" rowspan="1" colspan="1">N3b</td>
                  <td valign="top" align="center" rowspan="1" colspan="1">3/109</td>
                  <td valign="top" align="center" rowspan="1" colspan="1">yes</td>
                  <td valign="top" align="center" rowspan="1" colspan="1">2</td>
                  <td valign="top" align="left" rowspan="1" colspan="1">cyclosporine A, tacrolimus</td>
                </tr>
                <tr>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1">CSCC_0010</td>
                  <td valign="top" align="center" style="background-color: " rowspan="1" colspan="1">64</td>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1">male</td>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1">left scalp</td>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1">left neck</td>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1">N3b</td>
                  <td valign="top" align="center" style="background-color: " rowspan="1" colspan="1">2/11</td>
                  <td valign="top" align="center" style="background-color: " rowspan="1" colspan="1">yes</td>
                  <td valign="top" align="center" style="background-color: " rowspan="1" colspan="1">3</td>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1">no</td>
                </tr>
                <tr>
                  <td valign="top" align="left" rowspan="1" colspan="1">CSCC_0011</td>
                  <td valign="top" align="center" rowspan="1" colspan="1">69</td>
                  <td valign="top" align="left" rowspan="1" colspan="1">male</td>
                  <td valign="top" align="left" rowspan="1" colspan="1">unknown</td>
                  <td valign="top" align="left" rowspan="1" colspan="1">right parotid</td>
                  <td valign="top" align="left" rowspan="1" colspan="1">N3b</td>
                  <td valign="top" align="center" rowspan="1" colspan="1">3/108</td>
                  <td valign="top" align="center" rowspan="1" colspan="1">yes</td>
                  <td valign="top" align="center" rowspan="1" colspan="1">3</td>
                  <td valign="top" align="left" rowspan="1" colspan="1">no</td>
                </tr>
                <tr>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1">CSCC_0012</td>
                  <td valign="top" align="center" style="background-color: " rowspan="1" colspan="1">77</td>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1">male</td>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1">right nose</td>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1">right neck</td>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1">N3b</td>
                  <td valign="top" align="center" style="background-color: " rowspan="1" colspan="1">4/64</td>
                  <td valign="top" align="center" style="background-color: " rowspan="1" colspan="1">yes</td>
                  <td valign="top" align="center" style="background-color: " rowspan="1" colspan="1">2</td>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1">no</td>
                </tr>
                <tr>
                  <td valign="top" align="left" rowspan="1" colspan="1">CSCC_0013</td>
                  <td valign="top" align="center" rowspan="1" colspan="1">77</td>
                  <td valign="top" align="left" rowspan="1" colspan="1">male</td>
                  <td valign="top" align="left" rowspan="1" colspan="1">right pinna</td>
                  <td valign="top" align="left" rowspan="1" colspan="1">right parotid</td>
                  <td valign="top" align="left" rowspan="1" colspan="1">N3b</td>
                  <td valign="top" align="center" rowspan="1" colspan="1">1/1</td>
                  <td valign="top" align="center" rowspan="1" colspan="1">yes</td>
                  <td valign="top" align="center" rowspan="1" colspan="1">2</td>
                  <td valign="top" align="left" rowspan="1" colspan="1">no</td>
                </tr>
                <tr>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1">CSCC_0014</td>
                  <td valign="top" align="center" style="background-color: " rowspan="1" colspan="1">79</td>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1">female</td>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1">left cheek</td>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1">left perifacial</td>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1">N3b</td>
                  <td valign="top" align="center" style="background-color: " rowspan="1" colspan="1">1/1</td>
                  <td valign="top" align="center" style="background-color: " rowspan="1" colspan="1">yes</td>
                  <td valign="top" align="center" style="background-color: " rowspan="1" colspan="1">3</td>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1">no</td>
                </tr>
                <tr>
                  <td valign="top" align="left" rowspan="1" colspan="1">CSCC_0022</td>
                  <td valign="top" align="center" rowspan="1" colspan="1">66</td>
                  <td valign="top" align="left" rowspan="1" colspan="1">male</td>
                  <td valign="top" align="left" rowspan="1" colspan="1">scalp</td>
                  <td valign="top" align="left" rowspan="1" colspan="1">left neck</td>
                  <td valign="top" align="left" rowspan="1" colspan="1">N3b</td>
                  <td valign="top" align="center" rowspan="1" colspan="1">3/24</td>
                  <td valign="top" align="center" rowspan="1" colspan="1">yes</td>
                  <td valign="top" align="center" rowspan="1" colspan="1">3</td>
                  <td valign="top" align="left" rowspan="1" colspan="1">no</td>
                </tr>
                <tr>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1">CSCC_0024</td>
                  <td valign="top" align="center" style="background-color: " rowspan="1" colspan="1">54</td>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1">male</td>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1">lip</td>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1">right neck</td>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1">N3b</td>
                  <td valign="top" align="center" style="background-color: " rowspan="1" colspan="1">3/32</td>
                  <td valign="top" align="center" style="background-color: " rowspan="1" colspan="1">yes</td>
                  <td valign="top" align="center" style="background-color: " rowspan="1" colspan="1">2</td>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1">no</td>
                </tr>
                <tr>
                  <td valign="top" align="left" rowspan="1" colspan="1">CSCC_0025</td>
                  <td valign="top" align="center" rowspan="1" colspan="1">82</td>
                  <td valign="top" align="left" rowspan="1" colspan="1">male</td>
                  <td valign="top" align="left" rowspan="1" colspan="1">parotid</td>
                  <td valign="top" align="left" rowspan="1" colspan="1">Parotid</td>
                  <td valign="top" align="left" rowspan="1" colspan="1">N1</td>
                  <td valign="top" align="center" rowspan="1" colspan="1">1/15</td>
                  <td valign="top" align="center" rowspan="1" colspan="1">no</td>
                  <td valign="top" align="center" rowspan="1" colspan="1">3</td>
                  <td valign="top" align="left" rowspan="1" colspan="1">no</td>
                </tr>
                <tr>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1">CSCC_0066</td>
                  <td valign="top" align="center" style="background-color: " rowspan="1" colspan="1">56</td>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1">male</td>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1">Unknown</td>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1">Parotid</td>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1">N1</td>
                  <td valign="top" align="center" style="background-color: " rowspan="1" colspan="1">1/1</td>
                  <td valign="top" align="center" style="background-color: " rowspan="1" colspan="1">no</td>
                  <td valign="top" align="center" style="background-color: " rowspan="1" colspan="1">3</td>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1">no</td>
                </tr>
                <tr>
                  <td valign="top" align="left" rowspan="1" colspan="1">CSCC_0124</td>
                  <td valign="top" align="center" rowspan="1" colspan="1">80</td>
                  <td valign="top" align="left" rowspan="1" colspan="1">male</td>
                  <td valign="top" align="left" rowspan="1" colspan="1">Parotid</td>
                  <td valign="top" align="left" rowspan="1" colspan="1">Parotid</td>
                  <td valign="top" align="left" rowspan="1" colspan="1">N3b</td>
                  <td valign="top" align="center" rowspan="1" colspan="1">1/6</td>
                  <td valign="top" align="center" rowspan="1" colspan="1">yes</td>
                  <td valign="top" align="center" rowspan="1" colspan="1">Not stated</td>
                  <td valign="top" align="left" rowspan="1" colspan="1">no</td>
                </tr>
                <tr>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1">CSCC_0125</td>
                  <td valign="top" align="center" style="background-color: " rowspan="1" colspan="1">43</td>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1">male</td>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1">parotid</td>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1">parotid</td>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1">N3b</td>
                  <td valign="top" align="center" style="background-color: " rowspan="1" colspan="1">1/20</td>
                  <td valign="top" align="center" style="background-color: " rowspan="1" colspan="1">not stated</td>
                  <td valign="top" align="center" style="background-color: " rowspan="1" colspan="1">not stated</td>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1">no</td>
                </tr>
                <tr>
                  <td valign="top" align="left" rowspan="1" colspan="1">CSCC_0126</td>
                  <td valign="top" align="center" rowspan="1" colspan="1">66</td>
                  <td valign="top" align="left" rowspan="1" colspan="1">male</td>
                  <td valign="top" align="left" rowspan="1" colspan="1">left temple</td>
                  <td valign="top" align="left" rowspan="1" colspan="1">left neck</td>
                  <td valign="top" align="left" rowspan="1" colspan="1">N3b</td>
                  <td valign="top" align="center" rowspan="1" colspan="1">3/8</td>
                  <td valign="top" align="center" rowspan="1" colspan="1">yes</td>
                  <td valign="top" align="center" rowspan="1" colspan="1">3</td>
                  <td valign="top" align="left" rowspan="1" colspan="1">no</td>
                </tr>
                <tr>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1">CSCC_0130</td>
                  <td valign="top" align="center" style="background-color: " rowspan="1" colspan="1">70</td>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1">male</td>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1">unknown</td>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1">left parotid</td>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1">N3b</td>
                  <td valign="top" align="center" style="background-color: " rowspan="1" colspan="1">1/6</td>
                  <td valign="top" align="center" style="background-color: " rowspan="1" colspan="1">yes</td>
                  <td valign="top" align="center" style="background-color: " rowspan="1" colspan="1">3</td>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1">no</td>
                </tr>
                <tr>
                  <td valign="top" align="left" rowspan="1" colspan="1">CSCC_0132</td>
                  <td valign="top" align="center" rowspan="1" colspan="1">76</td>
                  <td valign="top" align="left" rowspan="1" colspan="1">male</td>
                  <td valign="top" align="left" rowspan="1" colspan="1">right ear</td>
                  <td valign="top" align="left" rowspan="1" colspan="1">parotid/neck</td>
                  <td valign="top" align="left" rowspan="1" colspan="1">N2b</td>
                  <td valign="top" align="center" rowspan="1" colspan="1">23/43</td>
                  <td valign="top" align="center" rowspan="1" colspan="1">no</td>
                  <td valign="top" align="center" rowspan="1" colspan="1">3</td>
                  <td valign="top" align="left" rowspan="1" colspan="1">no</td>
                </tr>
                <tr>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1">CSCC_0133</td>
                  <td valign="top" align="center" style="background-color: " rowspan="1" colspan="1">75</td>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1">male</td>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1">unknown</td>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1">parotid</td>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1">N3b</td>
                  <td valign="top" align="center" style="background-color: " rowspan="1" colspan="1">1/4</td>
                  <td valign="top" align="center" style="background-color: " rowspan="1" colspan="1">yes</td>
                  <td valign="top" align="center" style="background-color: " rowspan="1" colspan="1">not stated</td>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1">no</td>
                </tr>
                <tr>
                  <td valign="top" align="left" rowspan="1" colspan="1">CSCC_0134</td>
                  <td valign="top" align="center" rowspan="1" colspan="1">71</td>
                  <td valign="top" align="left" rowspan="1" colspan="1">male</td>
                  <td valign="top" align="left" rowspan="1" colspan="1">unknown</td>
                  <td valign="top" align="left" rowspan="1" colspan="1">right neck</td>
                  <td valign="top" align="left" rowspan="1" colspan="1">N3b</td>
                  <td valign="top" align="center" rowspan="1" colspan="1">9/17</td>
                  <td valign="top" align="center" rowspan="1" colspan="1">yes</td>
                  <td valign="top" align="center" rowspan="1" colspan="1">not stated</td>
                  <td valign="top" align="left" rowspan="1" colspan="1">no</td>
                </tr>
                <tr>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1">CSCC_0135</td>
                  <td valign="top" align="center" style="background-color: " rowspan="1" colspan="1">82</td>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1">male</td>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1">unknown</td>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1">right neck</td>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1">3b</td>
                  <td valign="top" align="center" style="background-color: " rowspan="1" colspan="1">1/48</td>
                  <td valign="top" align="center" style="background-color: " rowspan="1" colspan="1">yes</td>
                  <td valign="top" align="center" style="background-color: " rowspan="1" colspan="1">3</td>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1">no</td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn id="fnT1_1">
                <p>
<sup>1</sup>Staging according to AJCC 8th edition.</p>
              </fn>
            </table-wrap-foot>
            <table-wrap-foot>
              <fn id="fnT1_2">
                <p>
<sup>2</sup>Lymph node ratio (Number of positive nodes/total nodes harvested).</p>
              </fn>
            </table-wrap-foot>
            <table-wrap-foot>
              <fn id="fnT1_3">
                <p>
<sup>3</sup>Grade 1: well differentiated; Grade 2: moderately differentiated; Grade 3: poorly differentiated.</p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
        </sec>
        <sec id="s2_2">
          <title>Variant calling and functional significance of SNVs and indels</title>
          <p>FASTQ reads were aligned to reference genome GRChr38 using BWA-kit version 0.7.17 (BWA-MEM read aligner) (for details, refer to <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://github.com/Sydney-Informatics-Hub/Fastq-to-BAM">https://github.com/Sydney-Informatics-Hub/Fastq-to-BAM</uri>). The Genome Analysis Tool Kit (GATK) 4.1.2.0 and its BaseRecalibrator tool was used to refine the read alignment. SNPs and insertion–deletion (indel) variants were called by implementing GATK’s Best Practices Workflow. These pipelines use HaplotypeCaller for germline short variant discovery and Mutech2 caller for somatic short variant discovery for SNVs and indels (for details, refer to <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://github.com/Sydney-Informatics-Hub/Somatic-ShortV">https://github.com/Sydney-Informatics-Hub/Somatic-ShortV</uri>). Furthermore, variants effect prediction and annotations were completed using OpenCravat platform (<xref rid="B31" ref-type="bibr">31</xref>). Mutation Annotation Format (MAF) files were generated based on variant effect predictor annotations. Three different methods for driver discovery were then used; OncodriveFML (<xref rid="B32" ref-type="bibr">32</xref>), MutSigCV (<xref rid="B22" ref-type="bibr">22</xref>), and dNdScv (<xref rid="B33" ref-type="bibr">33</xref>).</p>
          <p>OncodriveFML predicts the functional significance of both coding and non-coding variants, as it is one of the few tools designed for non-coding genomic analysis (<xref rid="B32" ref-type="bibr">32</xref>). It first determines the functional impact of the observed somatic mutations using Combined Annotation Dependent Depletion (CADD) for specified genomic elements (UTR, promotor, and coding regions) across the cohort. Later, for the statistical significance, it compares the average functional impact score of the observed mutations in the element with the average functional impact scores of a similar number of the random mutational set. The CADD score provides a priority for identifying mutations with functional, deleterious, and pathogenic impacts. These scores are calculated by combining the information from multiple annotations into a single metric.</p>
          <p>MutSigCV identifies genes that are mutated more often than expected by chance and reduces the number of false positives in the generated list of significant genes, which is especially useful for tumors, such as metastatic CSCC, with high mutation rates (<xref rid="B22" ref-type="bibr">22</xref>). This is achieved by incorporating various types of information such as patient-specific mutation frequencies and mutation spectra, gene-specific mutation rates, expression levels, and replication times.</p>
          <p>dNdScv is designed to test for positive and negative selection in cancer genomes (<xref rid="B33" ref-type="bibr">33</xref>). As UV-induced cancer genomes such as CSCC can affect the accuracy of the dNdScv model, we carefully monitored the annotation of CC&gt;TT changes (sometimes reported as C&gt;T changes). Results report significance for missense and truncating mutations and indels as global p-values. Genes that were falsely flagged as significant with negative selection were not considered for this analysis.</p>
          <p>For downstream analysis, genes that were predicted to be driver genes by at least two of these tools were considered. First, genes with significant p-values &lt;0.005 were filtered from each of the three tools, and shared genes were determined using a Venn diagram. We then compared the functional impact of SNVs in these selected driver genes to previously reported primary and metastatic CSCC data (<xref rid="B18" ref-type="bibr">18</xref>, <xref rid="B19" ref-type="bibr">19</xref>, <xref rid="B21" ref-type="bibr">21</xref>, <xref rid="B34" ref-type="bibr">34</xref>) available on cBioportal (<xref rid="B35" ref-type="bibr">35</xref>). This included 92 samples of metastatic CSCC (WES= 10, targeted NGS = 82) and 88 samples of primary CSCC (WES=32, targeted NGS=56).</p>
        </sec>
        <sec id="s2_3">
          <title>Copy number variation</title>
          <p>Copy number alterations in the 25 metastatic genomes were derived using PURPLE (<xref rid="B30" ref-type="bibr">30</xref>), which estimates copy number and purity of tumor sample by using read depth ratio from COBALT and tumor B-allele frequency (BAF) from AMBER. The pipeline is available at github of HMF Tools (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://github.com/hartwigmedical/hmftools">https://github.com/hartwigmedical/hmftools</uri>). Driver genes with significant amplifications and deletions were then identified using PURPLE driver copy number outputs. For driver genes, PURPLE searches for genes with high level amplification (minimum exonic copy number &gt; 3 * sample ploidy) and deletion (minimum exonic copy number &lt; 0.5) and then uses iteration to establish the most significant focal peaks.</p>
          <p>GRIDSS2 and its companion interpreter tool LINX were employed for somatic structural variant analysis and gene fusion (<xref rid="B36" ref-type="bibr">36</xref>). COSMIC3-based SNVs and indels signatures from the whole genome were built using MutationalPatterns (<xref rid="B37" ref-type="bibr">37</xref>) software.</p>
          <p>The driver gene candidates obtained from various genetic alteration analyses such as copy number variation drivers, somatic variant drivers, and other non-coding drivers were combined for enrichment analysis. In the case of copy number gain/loss, we selected only those genes affected in &gt;20% of the samples in our cohort. Using the Enrichr web application (<xref rid="B38" ref-type="bibr">38</xref>), we determined the involvement of the candidate driver genes in various cellular components of the cells, biological pathways, and predicted miRNA and drug targets.</p>
        </sec>
      </sec>
      <sec sec-type="results" id="s3">
        <title>Results</title>
        <sec id="s3_1">
          <title>Patient characteristics and clinicopathological data</title>
          <p>Twenty-five metastatic CSCC samples from lymph nodes in the head and neck region were collected between 2015 and 2019 that passed WGS QC criteria for analysis (<xref rid="T1" ref-type="table"><bold>Table 1</bold></xref>). The median age of patients was 69 (range, 30–87), and 24/25 (96%) were male. While this sex disparity is a limitation of our study in that potential sex differences may have been missed, it is in keeping with the disease burden seen in our practice in NSW, Australia, particularly for advanced and metastatic CSCC (<xref rid="B39" ref-type="bibr">39</xref>). This is in keeping with findings that age, male sex, and immunosuppression are among the risk factors for metastasis (<xref rid="B40" ref-type="bibr">40</xref>). Two patients were immunocompromised; one patient was on long-term azathioprine for rheumatoid arthritis, and the other was on a combination of cyclophosphamide and tacrolimus following solid organ transplantation.</p>
          <p>The location of the index primary lesion was known in 11 patients (<xref rid="T1" ref-type="table"><bold>Table 1</bold></xref>). Nodal metastases were isolated from the neck in 13 patients and in the parotid in 12 patients. The majority of patients had either moderately differentiated (n = 8) or poorly differentiated (n = 12) CSCC, with evidence of extranodal extension found in 20/25 (80%) nodal samples.</p>
        </sec>
        <sec id="s3_2">
          <title>Tumor mutational burden</title>
          <p>Based on whole genome level calculations, the average tumor mutational burden (TMB) for SNVs and indels across the 25 cases was 238.7 mutations per megabase (median, 166.99 mutations/Mb; range, 32.52–995.66 mutations/Mb) and 2.25 indel/megabase (range, 0.63–5.9 mutations/Mb), respectively (<xref rid="f1" ref-type="fig"><bold>Figures 1A, B</bold></xref>; <xref rid="SM1" ref-type="supplementary-material"><bold>Supplementary Table S1</bold></xref>) with the majority of somatic variants occurring in the non-coding regions as expected (<xref rid="B12" ref-type="bibr">12</xref>). The only female tumor in this cohort had the second highest TMB at 499 mutations/Mb. There was no correlation between age, differentiation, nodal stage, or extracapsular spread of the metastasis and TMB.</p>
          <fig position="float" id="f1" orientation="portrait">
            <label>Figure 1</label>
            <caption>
              <p>Overview of tumor mutational burden and signatures (whole genome-based). Panels <bold>(A, B)</bold> illustrate the indel and SNV mutational burden in each sample, respectively. Panels <bold>(C, D)</bold> show indel (ID) and SNV mutational signatures for each sample, respectively, obtained using COSMIC V3.2 database. Full details are available in <xref rid="SM1" ref-type="supplementary-material"><bold>Supplementary Table S2</bold></xref>.</p>
            </caption>
            <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fonc-12-919118-g001.jpg"/>
          </fig>
        </sec>
        <sec id="s3_3">
          <title>Mutational signatures</title>
          <p>We performed mutational signature analyses of the 25 genomes based on COSMIC V.3.2 (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://cancer.sanger.ac.uk/signatures/">https://cancer.sanger.ac.uk/signatures/</uri>). Signatures are designated as single base substitution (SBS) or small insertion and deletion (ID) signatures. SBS signatures 7a and 7b were the most prevalent (<xref rid="f1" ref-type="fig"><bold>Figure 1C</bold></xref>; <xref rid="SM1" ref-type="supplementary-material"><bold>Supplementary Table S2</bold></xref>) in keeping with a UV association in metastatic CSCC as we previously reported in a smaller cohort using COSMIC V2 (<xref rid="B12" ref-type="bibr">12</xref>). Substantial representation of SBS7c was also seen. SBS32 and SBS7d were observed in one sample. Indel signature analysis showed that ID8, 9, and 13 dominated over others (<xref rid="f1" ref-type="fig"><bold>Figure 1D</bold></xref>; <xref rid="SM1" ref-type="supplementary-material"><bold>Supplementary Table S2</bold></xref>).</p>
        </sec>
        <sec id="s3_4">
          <title>Short variants</title>
          <sec id="s3_4_1">
            <title>Coding short variants</title>
            <p>The overwhelming majority of coding SNVs were missense mutations, followed by nonsense mutation, which represented &lt;5% of variants (<xref rid="f2" ref-type="fig"><bold>Figure 2A</bold></xref>). <xref rid="f2" ref-type="fig"><bold>Figure 2B</bold></xref> shows various DNA sequence alterations, including single, double, and triple nucleotide variants and insertion and deletion (<xref rid="SM1" ref-type="supplementary-material"><bold>Supplementary Data 1</bold></xref>). Over 80% of SNVs were C&gt;T (<xref rid="f2" ref-type="fig"><bold>Figures 2C, D</bold></xref>). This is consistent with the dominant effect of UV radiation on pyrimidine bases and the UV signature referred to above and is independent of the degree of differentiation or any other clinicopathological feature. Genes predicted to be driver genes <italic toggle="yes">via</italic> OncoDriveFML include <italic toggle="yes">TP53</italic>, <italic toggle="yes">CDKN2A</italic>, and <italic toggle="yes">ZNF730</italic> having Q-values &lt;0.1 (<xref rid="f2" ref-type="fig"><bold>Figure 2E</bold></xref>). MutSigCV and dNdScv analyses also found <italic toggle="yes">TP53</italic> and <italic toggle="yes">CDKN2A</italic> as the most significant mutated driver genes in our cohort (<xref rid="SM1" ref-type="supplementary-material"><bold>Supplementary Table S3</bold></xref>). Genes that were predicted to be driver genes (p-value &lt; 0.005) by at least two tools were considered for downstream analyses (<xref rid="f2" ref-type="fig"><bold>Figure 2F</bold></xref>). This resulted in 12 genes: <italic toggle="yes">TP53</italic>, <italic toggle="yes">CDKN2A</italic>, <italic toggle="yes">C9</italic>, <italic toggle="yes">C9orf131</italic>, <italic toggle="yes">SLC22A6</italic>, <italic toggle="yes">KHDRBS2</italic>, <italic toggle="yes">COLEC12</italic>, <italic toggle="yes">LINGO2</italic>, <italic toggle="yes">CDHR5</italic>, <italic toggle="yes">ZNF442</italic>, <italic toggle="yes">PRLR</italic>, and <italic toggle="yes">DHRS4</italic>. Of this list, <italic toggle="yes">TP53</italic>, <italic toggle="yes">CDKN2A</italic>, and <italic toggle="yes">C9</italic> were shared as significant by all three tools. Interrogation of the cBioPortal dataset for CSCC (metastatic = 92 and primary=88 cases) (<xref rid="B18" ref-type="bibr">18</xref>, <xref rid="B19" ref-type="bibr">19</xref>, <xref rid="B21" ref-type="bibr">21</xref>) with short variant analysis (<xref rid="SM1" ref-type="supplementary-material"><bold>Supplementary Figure S1</bold></xref>) revealed recurrent mutations not only in <italic toggle="yes">TP53</italic> and <italic toggle="yes">CDKN2A</italic> but also in <italic toggle="yes">C9</italic>, <italic toggle="yes">COLEC12</italic>, and <italic toggle="yes">SLC22A6.</italic> Not all genes identified as high impact and recurrent variants in our cohort were included in these targeted studies, which underscores the deficiencies of panel-based analyses in discovery projects.</p>
            <fig position="float" id="f2" orientation="portrait">
              <label>Figure 2</label>
              <caption>
                <p>Overview of key coding mutations. <bold>(A)</bold> Variants classification, <bold>(B)</bold> variant types, where SNP, DNP, TNP, INS, and DEL are single nucleotide polymorphisms, double nucleotide polymorphisms, triple nucleotide polymorphisms, insertion, and deletion, respectively (<bold>C</bold>, left panel) % of various transitions, (<bold>C</bold>, right panel) Ti (transition) and Tv (transversion) in all 25 samples, and <bold>(D)</bold> % transitions for each sample. <bold>(E)</bold> Driver coding genes prediction results from OncodriveFML tool. The plot shows the most significantly altered genes (in the plots above the red line, Q-values are below 0.1). Q-values are corrected p-values using the Benjamini/Hochberg correction. <bold>(F)</bold> Venn diagram showing the overlap of genes predicted to be driver genes (p-value &lt; 0.005) by three different driver detection tools, i.e., OncoDriveFML, MutSigCV, and dNdScv. (For details, refer to <xref rid="SM1" ref-type="supplementary-material"><bold>Supplementary Table S3</bold></xref>). For further analysis, genes predicted to be driver genes by at least two tools were considered. <bold>(G)</bold> Detailed sample-level information of the SNVs and types of variants in the top altered genes (mentioned in <xref rid="f2" ref-type="fig"><bold>Figure 2</bold></xref>).</p>
              </caption>
              <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fonc-12-919118-g002.jpg"/>
            </fig>
            <p>The only sample with no mutation in <italic toggle="yes">TP53</italic> was CSCC_0009 (<xref rid="f2" ref-type="fig"><bold>Figure 2G</bold></xref>). The TMB of this sample was 122/Mb or 51% of the average across the cohort. Five samples without <italic toggle="yes">CDKN2A</italic> mutations averaged a TMB of 470/Mb or 201% of the average for the cohort.</p>
          </sec>
          <sec id="s3_4_2">
            <title>Variation in non-coding regulatory regions</title>
            <p>The 3′UTRs that potentially play an important role in metastatic CSCC were discovered using OncodriveFML. SNVs within the 3′UTR region of <italic toggle="yes">EVC</italic>, <italic toggle="yes">PPP1R1A</italic>, <italic toggle="yes">ABCA4</italic>, and <italic toggle="yes">LUM</italic> showed significantly higher observed functional impact than the expected functional impact (Q-value &lt;0.03) (<xref rid="f3" ref-type="fig"><bold>Figure 3A</bold></xref>; <xref rid="SM1" ref-type="supplementary-material"><bold>Supplementary Table S3</bold></xref>). We observed variation within the 3′UTR of both <italic toggle="yes">EVC</italic> and <italic toggle="yes">PPP1R1A</italic> in 48% of samples with a Q-value of 0.011 and 0.022, respectively (<xref rid="f3" ref-type="fig"><bold>Figure 3B</bold></xref>; <xref rid="SM1" ref-type="supplementary-material"><bold>Supplementary Table S4</bold></xref>). The unique <italic toggle="yes">PPP1R1A</italic> variant with cDNA change of c.*491C&gt;T [Chr12:54579896 (G to A)] was found in five samples (<xref rid="SM1" ref-type="supplementary-material"><bold>Supplementary Figure S2</bold></xref>).</p>
            <fig position="float" id="f3" orientation="portrait">
              <label>Figure 3</label>
              <caption>
                <p>Driver genes prediction in non-coding genomic regions. Plots show the result of OncodrivFML (2.2.0) tool and mutations in the most significantly altered non-coding genes or regions in the cohort of 25 patient samples. <bold>(A)</bold> Potential 3′UTR regions associated driver candidates. <bold>(B)</bold> Variants with significantly altered 3′UTR regions. <bold>(C)</bold> Potential lncRNA driver candidates. <bold>(D)</bold> Variants with significantly altered lncRNAs. Plots in panels <bold>(A)</bold> and <bold>(C)</bold> show the frequency of observed mutations with respect to the expected frequency of the mutations in the corresponding regions. Q-values are corrected p-values using the Benjamini/Hochberg correction. The plots in panels <bold>(B, D)</bold> show frequencies of 3′UTR and lncRNAs variants among the cohorts, respectively.</p>
              </caption>
              <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fonc-12-919118-g003.jpg"/>
            </fig>
            <p>There are many reported limitations in the analysis and interpretation of 5′UTRs and promoters for high mutational burden tumors (<xref rid="B41" ref-type="bibr">41</xref>–<xref rid="B43" ref-type="bibr">43</xref>), a finding that we also observed (<xref rid="SM1" ref-type="supplementary-material"><bold>Supplementary Figure 3</bold></xref>). Currently, no robust methodology exists to analyze these regions with confidence in CSCC; thus, analyses of 5′UTRs and promoter regions were not investigated further.</p>
            <p>lncRNAs likely to have a potential impact on tumorigenesis were also predicted using OncodriveFML. Four lncRNAs were significantly (q &lt; 0.05) biased towards high-impact mutations i.e., <italic toggle="yes">LINC01474</italic> and <italic toggle="yes">LINC01003</italic>, <italic toggle="yes">RP4-597N16.4</italic>, and <italic toggle="yes">RP11-61J19.4</italic> (<xref rid="f3" ref-type="fig"><bold>Figure 3C</bold></xref>; <xref rid="SM1" ref-type="supplementary-material"><bold>Supplementary Table S3</bold></xref>). Among these, <italic toggle="yes">LINC01474</italic> and <italic toggle="yes">LINC01003</italic> showed a high statistical significance Q-value of 0.0158. lncRNA <italic toggle="yes">LINC01003</italic> was altered in 64% of the cohort. Another recurrently mutated lncRNA in our cohort was <italic toggle="yes">RP11-61J19.4</italic> (48% of samples) (<xref rid="f3" ref-type="fig"><bold>Figure 3D</bold></xref>; <xref rid="SM1" ref-type="supplementary-material"><bold>Supplementary Table S4</bold></xref>).</p>
          </sec>
        </sec>
        <sec id="s3_5">
          <title>Structural and copy number variation</title>
          <p>The extent of chromosomal copy number gain and loss was averaged across the genome for all 25 tumor samples (<xref rid="f4" ref-type="fig"><bold>Figure 4A</bold></xref>; <xref rid="SM1" ref-type="supplementary-material"><bold>Supplementary Table S5</bold></xref>). Chr5p and 8q were the most frequently amplified regions, with 18q being the region with the most recurrent deletion. At sample level (<xref rid="f4" ref-type="fig"><bold>Figure 4B</bold></xref>), there were chromosome arm gains in chromosome 7 and 5p in the majority of the samples and losses in 8p, 18q, and 21q. Recurrent gain of 7, 8q, and 5p and loss of 8p, 18, and 21 were also previously reported by Pickering et al. (<xref rid="B21" ref-type="bibr">21</xref>). <xref rid="f4" ref-type="fig"><bold>Figure 4B</bold></xref> also shows a Circos plot obtained from the PURPLE pipeline for CSCC_0004 as a representative example that summarizes various information at the sample level.</p>
          <fig position="float" id="f4" orientation="portrait">
            <label>Figure 4</label>
            <caption>
              <p>Chromosomal and recurrent genetic copy number variation. <bold>(A)</bold> Combined chromosomal CNV across 25 metastatic CSCC samples at the chromosomal level. The X-axis represents the differences of mean minimum copy number (bands) and means of overall samples ploidy (after adjustment for purity). Refer to <xref rid="SM1" ref-type="supplementary-material"><bold>Supplementary Table S5</bold></xref>. <bold>(B)</bold> Chromosomes arm loss and gain at the sample level (red denotes a gain, and blue denotes a loss). Both arms of chromosomes 7 and 5p show gains. 8p, 18q, and 21q show loss. (A chromosome arm is defined to be deleted if at least half of its bases are one or more copies less than the sample ploidy. A chromosome arm is defined to be amplified if at least half of its bases are one or more copies more than the sample ploidy.). Also shown is a Circos plot obtained from the PURPLE pipeline for CSCC_0004 as a representative example that summarizes various information at the sample level. (More details of interpretation at <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://github.com/hartwigmedical/hmftools/blob/master/purple/README.md#circos">https://github.com/hartwigmedical/hmftools/blob/master/purple/README.md#circos</uri>).</p>
            </caption>
            <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fonc-12-919118-g004.jpg"/>
          </fig>
          <p>Structural variation analysis revealed that CSCC metastases are characterized by various complex, deleted, and unbalanced translocation events. <xref rid="T2" ref-type="table"><bold>Table 2</bold></xref> provides the summary of various structural events observed. Deletion and complex structural variants are common in CSCC; however, unbalanced translocation and other structural events were also observed (<xref rid="T2" ref-type="table"><bold>Table 2</bold></xref>). The detailed effects of these structural events for putative oncogenes and tumor suppressor genes (TSGs) are described in <xref rid="T3" ref-type="table"><bold>Table 3</bold></xref>. Amplification events are linked to complex structural variants. Potential oncogene/TSG driver amplification and deletion were predicted by the PURPLE-GRIDSS-LINX pipeline, as reported in <xref rid="T3" ref-type="table"><bold>Table 3</bold></xref>. Recurrent gene deletions were more common than gene amplifications. The most frequently deleted gene was <italic toggle="yes">PTPRD (</italic>Chr9p, 24% of samples). <italic toggle="yes">PTPRD</italic> deletion is already reported in primary and metastatic CSCC (<xref rid="B44" ref-type="bibr">44</xref>, <xref rid="B45" ref-type="bibr">45</xref>). Deletion of <italic toggle="yes">PTPRD</italic> (n=6) and <italic toggle="yes">CDKN2A</italic> (Chr9p) (n=1) did not co-occur in our cohort (<xref rid="T3" ref-type="table"><bold>Table 3</bold></xref>), although <italic toggle="yes">PTPRD</italic> loss and significant mutation of <italic toggle="yes">CDKN2A</italic> co<italic toggle="yes">-</italic>occurred in six samples (CSCC_9, 11, 12, 133, 132, and 134) (<xref rid="T3" ref-type="table"><bold>Table 3</bold></xref>; <xref rid="f2" ref-type="fig"><bold>Figure 2G</bold></xref>). Deep deletion of <italic toggle="yes">CDKN2A</italic> was reported in only 2/92 cases available on cBioPortal (<xref rid="SM1" ref-type="supplementary-material"><bold>Supplementary Figure S1</bold></xref>).</p>
          <table-wrap position="float" id="T2" orientation="portrait">
            <label>Table 2</label>
            <caption>
              <p>Summary of various event categories of structural variants.</p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th valign="top" align="left" rowspan="1" colspan="1">Sample</th>
                  <th valign="top" align="center" rowspan="1" colspan="1">SGL</th>
                  <th valign="top" align="center" rowspan="1" colspan="1">DEL</th>
                  <th valign="top" align="center" rowspan="1" colspan="1">DUP</th>
                  <th valign="top" align="left" rowspan="1" colspan="1">Complex</th>
                  <th valign="top" align="center" rowspan="1" colspan="1">UNBAL_trans</th>
                  <th valign="top" align="center" rowspan="1" colspan="1">Pair.other</th>
                  <th valign="top" align="center" rowspan="1" colspan="1">INF</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1">CSCC_0001</td>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1">
<italic toggle="yes">SMAD4</italic>
</td>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1">
<italic toggle="yes">SMAD4</italic>
</td>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1"/>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1"/>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1"/>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1"/>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1">
<italic toggle="yes"> </italic>
</td>
                </tr>
                <tr>
                  <td valign="top" align="left" rowspan="1" colspan="1">CSCC_0002</td>
                  <td valign="top" align="left" rowspan="1" colspan="1"/>
                  <td valign="top" align="left" rowspan="1" colspan="1">
<italic toggle="yes">CDKN2A</italic>
</td>
                  <td valign="top" align="left" rowspan="1" colspan="1"/>
                  <td valign="top" align="left" rowspan="1" colspan="1"/>
                  <td valign="top" align="left" rowspan="1" colspan="1"/>
                  <td valign="top" align="left" rowspan="1" colspan="1"/>
                  <td valign="top" align="left" rowspan="1" colspan="1">
<italic toggle="yes"> </italic>
</td>
                </tr>
                <tr>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1">CSCC_0005</td>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1"/>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1"/>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1">
<italic toggle="yes">MYC</italic>
</td>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1">
<italic toggle="yes">MYC</italic>
</td>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1"/>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1"/>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1">
<italic toggle="yes"> </italic>
</td>
                </tr>
                <tr>
                  <td valign="top" align="left" rowspan="1" colspan="1">CSCC_0007</td>
                  <td valign="top" align="left" rowspan="1" colspan="1"/>
                  <td valign="top" align="left" rowspan="1" colspan="1"/>
                  <td valign="top" align="left" rowspan="1" colspan="1"/>
                  <td valign="top" align="left" rowspan="1" colspan="1">
<italic toggle="yes">CRLF2</italic>
</td>
                  <td valign="top" align="left" rowspan="1" colspan="1"/>
                  <td valign="top" align="left" rowspan="1" colspan="1"/>
                  <td valign="top" align="left" rowspan="1" colspan="1">
<italic toggle="yes"> </italic>
</td>
                </tr>
                <tr>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1">CSCC_0009</td>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1"/>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1">
<italic toggle="yes">PTPRD</italic>
</td>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1"/>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1"/>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1"/>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1"/>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1">
<italic toggle="yes"> </italic>
</td>
                </tr>
                <tr>
                  <td valign="top" align="left" rowspan="1" colspan="1">CSCC_0011</td>
                  <td valign="top" align="left" rowspan="1" colspan="1"/>
                  <td valign="top" align="left" rowspan="1" colspan="1">
<italic toggle="yes">PTPRD</italic>
</td>
                  <td valign="top" align="left" rowspan="1" colspan="1"/>
                  <td valign="top" align="left" rowspan="1" colspan="1">
<italic toggle="yes">CALR</italic>
</td>
                  <td valign="top" align="left" rowspan="1" colspan="1">
<italic toggle="yes">HEBP2- NTRK2</italic>
</td>
                  <td valign="top" align="left" rowspan="1" colspan="1"/>
                  <td valign="top" align="left" rowspan="1" colspan="1">
<italic toggle="yes"> </italic>
</td>
                </tr>
                <tr>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1">CSCC_0012</td>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1"/>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1">
<italic toggle="yes">PTPRD</italic>
</td>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1"/>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1">
<italic toggle="yes">EGFR</italic>
</td>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1"/>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1">
<italic toggle="yes">PTPRD</italic>
</td>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1">
<italic toggle="yes"> </italic>
</td>
                </tr>
                <tr>
                  <td valign="top" align="left" rowspan="1" colspan="1">CSCC_0013</td>
                  <td valign="top" align="left" rowspan="1" colspan="1"/>
                  <td valign="top" align="left" rowspan="1" colspan="1">
<italic toggle="yes">APC</italic>
</td>
                  <td valign="top" align="left" rowspan="1" colspan="1"/>
                  <td valign="top" align="left" rowspan="1" colspan="1"/>
                  <td valign="top" align="left" rowspan="1" colspan="1"/>
                  <td valign="top" align="left" rowspan="1" colspan="1"/>
                  <td valign="top" align="left" rowspan="1" colspan="1">
<italic toggle="yes"> </italic>
</td>
                </tr>
                <tr>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1">CSCC_0014</td>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1"/>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1">
<italic toggle="yes">CREBBP</italic>
</td>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1"/>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1"/>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1"/>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1"/>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1">
<italic toggle="yes">CREBBP</italic>
</td>
                </tr>
                <tr>
                  <td valign="top" align="left" rowspan="1" colspan="1">CSCC_0025</td>
                  <td valign="top" align="left" rowspan="1" colspan="1"/>
                  <td valign="top" align="left" rowspan="1" colspan="1">
<italic toggle="yes">CDKN2C</italic>
</td>
                  <td valign="top" align="left" rowspan="1" colspan="1"/>
                  <td valign="top" align="left" rowspan="1" colspan="1"/>
                  <td valign="top" align="left" rowspan="1" colspan="1">
<italic toggle="yes">PARD6G</italic>
</td>
                  <td valign="top" align="left" rowspan="1" colspan="1"/>
                  <td valign="top" align="left" rowspan="1" colspan="1">
<italic toggle="yes"> </italic>
</td>
                </tr>
                <tr>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1">CSCC_0066</td>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1"/>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1">
<italic toggle="yes">PTPN13</italic>
</td>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1"/>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1"/>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1"/>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1"/>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1">
<italic toggle="yes"> </italic>
</td>
                </tr>
                <tr>
                  <td valign="top" align="left" rowspan="1" colspan="1">CSCC_0124</td>
                  <td valign="top" align="left" rowspan="1" colspan="1"/>
                  <td valign="top" align="left" rowspan="1" colspan="1">
<italic toggle="yes">NEGR1</italic>
</td>
                  <td valign="top" align="left" rowspan="1" colspan="1"/>
                  <td valign="top" align="left" rowspan="1" colspan="1"/>
                  <td valign="top" align="left" rowspan="1" colspan="1"/>
                  <td valign="top" align="left" rowspan="1" colspan="1">
<italic toggle="yes">NEGR1</italic>
</td>
                  <td valign="top" align="left" rowspan="1" colspan="1">
<italic toggle="yes"> </italic>
</td>
                </tr>
                <tr>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1">CSCC_0132</td>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1"/>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1">
<italic toggle="yes">PTPRD</italic>
</td>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1"/>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1">
<italic toggle="yes">RAF1-FGF3-CCND1</italic>
</td>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1"/>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1"/>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1"> </td>
                </tr>
                <tr>
                  <td valign="top" align="left" rowspan="1" colspan="1">CSCC_0133</td>
                  <td valign="top" align="left" rowspan="1" colspan="1">
<italic toggle="yes">PTPRD</italic>
</td>
                  <td valign="top" align="left" rowspan="1" colspan="1">
<italic toggle="yes">PTPRD</italic>
</td>
                  <td valign="top" align="left" rowspan="1" colspan="1"/>
                  <td valign="top" align="left" rowspan="1" colspan="1">CALR-chr1-chr3-chr6-chr8-chr22</td>
                  <td valign="top" align="left" rowspan="1" colspan="1"/>
                  <td valign="top" align="left" rowspan="1" colspan="1"/>
                  <td valign="top" align="left" rowspan="1" colspan="1"> </td>
                </tr>
                <tr>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1">CSCC_0134</td>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1"/>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1"/>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1"/>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1">
<italic toggle="yes">MCL1, CCND1-FGF3</italic>-Chr17</td>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1"/>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1"/>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1"> </td>
                </tr>
                <tr>
                  <td valign="top" align="left" rowspan="1" colspan="1">CSCC_0135</td>
                  <td valign="top" align="left" rowspan="1" colspan="1"> </td>
                  <td valign="top" align="left" rowspan="1" colspan="1">
<italic toggle="yes">PTPRD</italic>
</td>
                  <td valign="top" align="left" rowspan="1" colspan="1"> </td>
                  <td valign="top" align="left" rowspan="1" colspan="1"> </td>
                  <td valign="top" align="left" rowspan="1" colspan="1"> </td>
                  <td valign="top" align="left" rowspan="1" colspan="1"> </td>
                  <td valign="top" align="left" rowspan="1" colspan="1"> </td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn>
                <p>For more details, refer to <xref rid="SM1" ref-type="supplementary-material"><bold>Supplementary Figures S4</bold></xref> and <xref rid="SM1" ref-type="supplementary-material"><bold>S5</bold></xref>. Association can be noted between gain (<xref rid="T3" ref-type="table"><bold>Table 3</bold></xref>) and complex SV events. The gene list was derived using LINX output. Only samples with events are shown in the table.</p>
              </fn>
              <fn>
                <p>NBAL_TRANS, unbalanced translocation; INF, inferred breakend; DEL, deletion; DUP, duplication; SGL, single breakend SV support</p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
          <table-wrap position="float" id="T3" orientation="portrait">
            <label>Table 3</label>
            <caption>
              <p>List of reportable drivers (likelihood type onco/TSG) genes.</p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th valign="top" align="left" rowspan="1" colspan="1">Sample</th>
                  <th valign="top" align="left" rowspan="1" colspan="1">DEL</th>
                  <th valign="top" align="left" rowspan="1" colspan="1">GAIN</th>
                  <th valign="top" align="left" rowspan="1" colspan="1">LOH_CHR</th>
                  <th valign="top" align="center" rowspan="1" colspan="1">LOH_ARM</th>
                  <th valign="top" align="center" rowspan="1" colspan="1">LOH</th>
                  <th valign="top" align="center" rowspan="1" colspan="1">LOH_SV_TELO</th>
                  <th valign="top" align="center" rowspan="1" colspan="1">LOH_SV_CENTRO</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1">CSCC_0001</td>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1">
<italic toggle="yes">SMAD4</italic>
</td>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1"/>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1"/>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1"/>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1"/>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1">
<italic toggle="yes">SMAD4</italic>
</td>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1">
<italic toggle="yes"> </italic>
</td>
                </tr>
                <tr>
                  <td valign="top" align="left" rowspan="1" colspan="1">CSCC_0002</td>
                  <td valign="top" align="left" rowspan="1" colspan="1">
<italic toggle="yes">CDKN2A</italic>
</td>
                  <td valign="top" align="left" rowspan="1" colspan="1"/>
                  <td valign="top" align="left" rowspan="1" colspan="1"/>
                  <td valign="top" align="left" rowspan="1" colspan="1"/>
                  <td valign="top" align="left" rowspan="1" colspan="1"/>
                  <td valign="top" align="left" rowspan="1" colspan="1"/>
                  <td valign="top" align="left" rowspan="1" colspan="1">
<italic toggle="yes"> </italic>
</td>
                </tr>
                <tr>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1">CSCC_0003</td>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1">
<italic toggle="yes">KDM6A</italic>
</td>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1"/>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1">
<italic toggle="yes">KDM6A</italic>
</td>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1"/>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1"/>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1"/>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1">
<italic toggle="yes"> </italic>
</td>
                </tr>
                <tr>
                  <td valign="top" align="left" rowspan="1" colspan="1">CSCC_0005</td>
                  <td valign="top" align="left" rowspan="1" colspan="1">
<italic toggle="yes"> </italic>
</td>
                  <td valign="top" align="left" rowspan="1" colspan="1">
<italic toggle="yes">MYC</italic>
</td>
                  <td valign="top" align="left" rowspan="1" colspan="1"/>
                  <td valign="top" align="left" rowspan="1" colspan="1"/>
                  <td valign="top" align="left" rowspan="1" colspan="1"/>
                  <td valign="top" align="left" rowspan="1" colspan="1"/>
                  <td valign="top" align="left" rowspan="1" colspan="1">
<italic toggle="yes"> </italic>
</td>
                </tr>
                <tr>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1">CSCC_0007</td>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1">
<italic toggle="yes"> </italic>
</td>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1">
<italic toggle="yes">CRLF2</italic>
</td>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1"/>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1"/>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1"/>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1"/>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1">
<italic toggle="yes"> </italic>
</td>
                </tr>
                <tr>
                  <td valign="top" align="left" rowspan="1" colspan="1">CSCC_0009</td>
                  <td valign="top" align="left" rowspan="1" colspan="1">
<italic toggle="yes">PTPRD</italic>
</td>
                  <td valign="top" align="left" rowspan="1" colspan="1"/>
                  <td valign="top" align="left" rowspan="1" colspan="1"/>
                  <td valign="top" align="left" rowspan="1" colspan="1">
<italic toggle="yes">PTPRD</italic>
</td>
                  <td valign="top" align="left" rowspan="1" colspan="1"/>
                  <td valign="top" align="left" rowspan="1" colspan="1"/>
                  <td valign="top" align="left" rowspan="1" colspan="1">
<italic toggle="yes"> </italic>
</td>
                </tr>
                <tr>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1">CSCC_0011</td>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1">
<italic toggle="yes">PTPRD</italic>
</td>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1">
<italic toggle="yes">CALR</italic>
</td>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1"/>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1">
<italic toggle="yes">PTPRD</italic>
</td>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1"/>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1"/>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1">
<italic toggle="yes"> </italic>
</td>
                </tr>
                <tr>
                  <td valign="top" align="left" rowspan="1" colspan="1">CSCC_0012</td>
                  <td valign="top" align="left" rowspan="1" colspan="1">
<italic toggle="yes">PTPRD</italic>
</td>
                  <td valign="top" align="left" rowspan="1" colspan="1">
<italic toggle="yes">EGFR</italic>
</td>
                  <td valign="top" align="left" rowspan="1" colspan="1">
<italic toggle="yes">PPP2R3B, PUDP, STS,WWC3</italic>
</td>
                  <td valign="top" align="left" rowspan="1" colspan="1"/>
                  <td valign="top" align="left" rowspan="1" colspan="1">
<italic toggle="yes">PTPRD</italic>
</td>
                  <td valign="top" align="left" rowspan="1" colspan="1"/>
                  <td valign="top" align="left" rowspan="1" colspan="1">
<italic toggle="yes"> </italic>
</td>
                </tr>
                <tr>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1">CSCC_0013</td>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1">
<italic toggle="yes">APC</italic>
</td>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1"/>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1"/>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1">
<italic toggle="yes">APC</italic>
</td>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1"/>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1"/>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1">
<italic toggle="yes"> </italic>
</td>
                </tr>
                <tr>
                  <td valign="top" align="left" rowspan="1" colspan="1">CSCC_0014</td>
                  <td valign="top" align="left" rowspan="1" colspan="1">
<italic toggle="yes">CREBBP</italic>
</td>
                  <td valign="top" align="left" rowspan="1" colspan="1"/>
                  <td valign="top" align="left" rowspan="1" colspan="1"/>
                  <td valign="top" align="left" rowspan="1" colspan="1"/>
                  <td valign="top" align="left" rowspan="1" colspan="1"/>
                  <td valign="top" align="left" rowspan="1" colspan="1">
<italic toggle="yes">CREBBP</italic>
</td>
                  <td valign="top" align="left" rowspan="1" colspan="1">
<italic toggle="yes"> </italic>
</td>
                </tr>
                <tr>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1">CSCC_0025</td>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1">
<italic toggle="yes">CDKN2C, PARD6G</italic>
</td>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1"/>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1">
<italic toggle="yes">PARD6G</italic>
</td>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1">
<italic toggle="yes">CDKN2C</italic>
</td>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1"/>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1"/>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1">
<italic toggle="yes"> </italic>
</td>
                </tr>
                <tr>
                  <td valign="top" align="left" rowspan="1" colspan="1">CSCC_0066</td>
                  <td valign="top" align="left" rowspan="1" colspan="1">
<italic toggle="yes">PTPN13</italic>
</td>
                  <td valign="top" align="left" rowspan="1" colspan="1"/>
                  <td valign="top" align="left" rowspan="1" colspan="1">
<italic toggle="yes">PTPN13</italic>
</td>
                  <td valign="top" align="left" rowspan="1" colspan="1"/>
                  <td valign="top" align="left" rowspan="1" colspan="1"/>
                  <td valign="top" align="left" rowspan="1" colspan="1"/>
                  <td valign="top" align="left" rowspan="1" colspan="1">
<italic toggle="yes"> </italic>
</td>
                </tr>
                <tr>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1">CSCC_0124</td>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1">
<italic toggle="yes">NEGR1</italic>
</td>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1"/>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1"/>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1"/>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1">
<italic toggle="yes">NEGR1</italic>
</td>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1"/>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1">
<italic toggle="yes"> </italic>
</td>
                </tr>
                <tr>
                  <td valign="top" align="left" rowspan="1" colspan="1">CSCC_0132</td>
                  <td valign="top" align="left" rowspan="1" colspan="1">
<italic toggle="yes">PTPRD</italic>
</td>
                  <td valign="top" align="left" rowspan="1" colspan="1">
<italic toggle="yes">RAF1,CCND1,FGF3</italic>
</td>
                  <td valign="top" align="left" rowspan="1" colspan="1"/>
                  <td valign="top" align="left" rowspan="1" colspan="1">
<italic toggle="yes">PTPRD</italic>
</td>
                  <td valign="top" align="left" rowspan="1" colspan="1"/>
                  <td valign="top" align="left" rowspan="1" colspan="1"/>
                  <td valign="top" align="left" rowspan="1" colspan="1">
<italic toggle="yes"> </italic>
</td>
                </tr>
                <tr>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1">CSCC_0133</td>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1">
<italic toggle="yes">PTPRD</italic>
</td>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1">
<italic toggle="yes">CALR</italic>
</td>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1"/>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1"/>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1"/>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1"/>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1">
<italic toggle="yes">PTPRD</italic>
</td>
                </tr>
                <tr>
                  <td valign="top" align="left" rowspan="1" colspan="1">CSCC_0134</td>
                  <td valign="top" align="left" rowspan="1" colspan="1">
<italic toggle="yes"> </italic>
</td>
                  <td valign="top" align="left" rowspan="1" colspan="1">
<italic toggle="yes">MCL1,CCND1,FGF3</italic>
</td>
                  <td valign="top" align="left" rowspan="1" colspan="1"/>
                  <td valign="top" align="left" rowspan="1" colspan="1"/>
                  <td valign="top" align="left" rowspan="1" colspan="1"/>
                  <td valign="top" align="left" rowspan="1" colspan="1"/>
                  <td valign="top" align="left" rowspan="1" colspan="1">
<italic toggle="yes"> </italic>
</td>
                </tr>
                <tr>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1">CSCC_0135</td>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1">
<italic toggle="yes">PTPRD</italic>
</td>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1">
<italic toggle="yes"> </italic>
</td>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1">
<italic toggle="yes"> </italic>
</td>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1">
<italic toggle="yes">PTPRD</italic>
</td>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1">
<italic toggle="yes"> </italic>
</td>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1">
<italic toggle="yes"> </italic>
</td>
                  <td valign="top" align="left" style="background-color: " rowspan="1" colspan="1">
<italic toggle="yes"> </italic>
</td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn>
                <p>The types of drivers are as follows: GAIN, amplification by SV; DEL, homozygous deletion; LOH, focal LOH; LOH_ARM, chromosome arm level LOH; LOH_CHR, chromosome level LOH; LOH_SV_TELO, LOH from SV to telomere; LOH_SV_CENTRO, LOH from SV to centromere. Only samples with events are shown in the table.</p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
          <p>Loss of heterozygosity (LOH) was found at the focal, arm, chromosome, telomere, and centromere levels. The most common LOH events were that at the chromosome and arm level with these events concentrated to <italic toggle="yes">PTPRD</italic> locus (<xref rid="T3" ref-type="table"><bold>Table 3</bold></xref>). No recurrent events for other genes were observed (<xref rid="T3" ref-type="table"><bold>Table 3</bold></xref>). Various examples of <italic toggle="yes">PTPRD</italic> structural events are reported in <xref rid="SM1" ref-type="supplementary-material"><bold>Supplementary Figure S4</bold></xref>. A few other examples of the unbalanced translocation and complex structural variants are shown in <xref rid="SM1" ref-type="supplementary-material"><bold>Supplementary Figure S5</bold></xref>.</p>
          <p>The most frequently amplified genes (2/25, 8%) were <italic toggle="yes">CALR</italic>, <italic toggle="yes">CCND1</italic>, and <italic toggle="yes">FGF3</italic> (<xref rid="T3" ref-type="table"><bold>Table 3</bold></xref>). Interestingly, <italic toggle="yes">EGFR</italic> was amplified in only one sample. Amplification of <italic toggle="yes">CCDN1</italic> and <italic toggle="yes">FGF3</italic> co-occurred in two samples (CSCC_0134 and CSCC_0132). <italic toggle="yes">CCDN1</italic> and <italic toggle="yes">FGF3</italic> are next to each other on the chromosome. These two cases had extensive nodal involvement (&gt;50% of lymph nodes harboring tumor).</p>
          <p>Despite this widespread genomic instability, only two coding–coding gene fusions were observed in our cohort. The first was between <italic toggle="yes">STRN</italic> and <italic toggle="yes">DLG2</italic> in sample CSCC_0009 (<italic toggle="yes">STRN</italic>: exon 1 ENST00000263918; <italic toggle="yes">DLG2</italic>: exon 7 ENST00000376104). <italic toggle="yes">STRN</italic> encodes a calcium-dependent calmodulin-binding protein (<xref rid="B46" ref-type="bibr">46</xref>). <italic toggle="yes">DLG2</italic> plays a role in pain signaling, and deletion is seen in both human and canine osteosarcoma (<xref rid="B47" ref-type="bibr">47</xref>). We noted above that CSCC_0009 is the only sample without <italic toggle="yes">TP53</italic> mutations. CSCC_0009 came from a patient who had undergone liver transplantation and was on immunosuppressive therapy. The primary tumor that gave rise to this metastasis showed perineural involvement, which was also present in the metastatic deposit. The second gene fusion was between <italic toggle="yes">NTRK2</italic> and <italic toggle="yes">HEBP2</italic> in CSCC_0011. This seems to be caused by an unbalanced translocation event (<xref rid="SM1" ref-type="supplementary-material"><bold>Supplementary Figure S5B</bold></xref>).</p>
        </sec>
        <sec id="s3_6">
          <title>Enrichment analysis</title>
          <p>Gene enrichment analysis was performed using the 21 genetically altered candidates identified above as significant/candidate driver genes, i.e., <italic toggle="yes">TP53</italic>, <italic toggle="yes">CDKN2A</italic>, <italic toggle="yes">C9</italic>, <italic toggle="yes">KHDRBS2</italic>, <italic toggle="yes">SLC22A6</italic>, <italic toggle="yes">COLEC12</italic>, <italic toggle="yes">LINGO2</italic>, <italic toggle="yes">CDHR5</italic>, <italic toggle="yes">ZNF442</italic>, <italic toggle="yes">C9orf131</italic>, <italic toggle="yes">PRLR</italic>, <italic toggle="yes">DHRS4</italic>, <italic toggle="yes">PPP1R1A</italic>, <italic toggle="yes">EVC</italic>, <italic toggle="yes">LUM</italic>, <italic toggle="yes">ABCA4</italic>, <italic toggle="yes">LINC01003</italic>, <italic toggle="yes">LINC01474 (RP11-151D14.1)</italic>, <italic toggle="yes">RP4-597N16.4</italic>, <italic toggle="yes">RP11-61J19.4</italic>, and <italic toggle="yes">PTPRD</italic>. The top significant pathway enrichment terms [Bio Planet 2019 (<xref rid="B48" ref-type="bibr">48</xref>)] are shown in <xref rid="f5" ref-type="fig"><bold>Figure 5A</bold></xref>. Most of the significant BioPlanet-enriched terms come from <italic toggle="yes">TP53</italic> and <italic toggle="yes">CDKN2A</italic>, such as TP53 network, tumor suppressor ARF, CTCF pathway, and cell cycle (G1/S checkpoint). However, <italic toggle="yes">CDKN2A</italic>, <italic toggle="yes">LUM</italic>, <italic toggle="yes">CDHR5</italic>, and <italic toggle="yes">COLEC12</italic> contribute to important cancer-related enrichment pathways, such as “TGF-beta regulation of extracellular matrix.” Full details of these enrichment analyses are available in <xref rid="SM1" ref-type="supplementary-material"><bold>Supplementary Table S6</bold></xref>.</p>
          <fig position="float" id="f5" orientation="portrait">
            <label>Figure 5</label>
            <caption>
              <p>Enrichment analysis results of genetically mutated genes (21 candidates). <bold>(A)</bold> GO-Cellular Component terms showing eight significantly enriched terms (obtained from BioPlanet 2019). Panels <bold>(B, C)</bold> showing most significant Jensen diseases and Jensen compartments enriched terms, respectively. For details, refer to <xref rid="SM1" ref-type="supplementary-material"><bold>Supplementary Table S6</bold></xref>.</p>
            </caption>
            <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fonc-12-919118-g005.jpg"/>
          </fig>
          <p>The Jensen diseases enrichment tool identified skin cancer with highest significance (<xref rid="f5" ref-type="fig"><bold>Figure 5B</bold></xref>), with Jensen compartment-based enrichment analysis showing that most of these genes belong to the extracellular compartment (<xref rid="f5" ref-type="fig"><bold>Figure 5C</bold></xref>). Other ontology enrichment analysis (MGI mammalian phenotype level 4 2021; <xref rid="SM1" ref-type="supplementary-material"><bold>Supplementary Table S6</bold></xref>) showed enrichment of increased fibroblast proliferation MP:0011703 where <italic toggle="yes">CDKN2A</italic>, <italic toggle="yes">TP53</italic>, and <italic toggle="yes">LUM</italic> alterations are the main contributors.</p>
          <p>We also performed enrichment analyses to predict drugs and miRNA targets for these driver candidates. <xref rid="f6" ref-type="fig"><bold>Figure 6A</bold></xref> shows the top 10 significant hits against drug annotations, which suggests that many of these driver genes are known therapeutic targets (dSig; <xref rid="SM1" ref-type="supplementary-material"><bold>Supplementary Table S6</bold></xref>). With respect to miRNA targets, <italic toggle="yes">hsa-miR-331-5p</italic> was predicted to interact with six driver gene candidates, including <italic toggle="yes">TP53</italic> and <italic toggle="yes">C9</italic> (<xref rid="f6" ref-type="fig"><bold>Figure 6B</bold></xref>). For this prediction, the enricher platform uses TargetScan miRNA database (<xref rid="B50" ref-type="bibr">50</xref>). At the same time, <italic toggle="yes">hsa-miR-1181</italic> was one of the most significantly enriched miRNAs for these driver candidates, but can target only two driver genes.</p>
          <fig position="float" id="f6" orientation="portrait">
            <label>Figure 6</label>
            <caption>
              <p>Enrichment analysis results for drug and miRNA targets. <bold>(A)</bold> Over-enrichment analysis of 20 driver candidates (deleted <italic toggle="yes">PTPRD</italic> excluded) against DSigDB (Drug SIGnatures DataBase) (<xref rid="B49" ref-type="bibr">49</xref>) annotation showing top 10 significantly enriched Drug/Compound. <bold>(B)</bold> Computationally predicted targets of miRNAs (TargetScan miRNA 2017). The x-axis represents the significance of the term (decreasing from left to right). (For details, refer to <xref rid="SM1" ref-type="supplementary-material"><bold>Supplementary Table S6</bold></xref>).</p>
            </caption>
            <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fonc-12-919118-g006.jpg"/>
          </fig>
        </sec>
      </sec>
      <sec sec-type="discussion" id="s4">
        <title>Discussion</title>
        <p>This is the largest study to employ WGS to assess the mutational landscape of metastatic CSCC and demonstrates the breadth of somatic variation across non-coding and coding regions. Furthermore, we updated and expanded the understanding of UV-mutational signature patterns in metastatic CSCC (<xref rid="B12" ref-type="bibr">12</xref>), including the identification of novel indel (ID) signature patterns. This highlights for the first time the nature and depth of variation within regulatory regions, with special attention devoted to UTR and lncRNA. Additionally, we reported various structural events at whole genome scale for this diseases and also compared driver genes and SNVs to previous WES/targeted NGS studies on metastasis CSCC.</p>
        <p>At 238 mutations/Mb (median of 166.99 mutations/Mb) within metastatic CSCC at the whole genome scale, the rate of TMB is substantially higher than that of other cancers known to have a high mutational burden, including melanoma, which is 49 mutations/Mb (<xref rid="B51" ref-type="bibr">51</xref>). Pickering et al. (<xref rid="B21" ref-type="bibr">21</xref>) found a median of 61.2 mutations/Mb from their WES of high-risk primary (n= 32) and metastatic (n =7) CSCC. Their finding shows lower TMB than our study because they analyzed only coding DNA, which has much lower TMB than non-coding DNA in CSCC (<xref rid="B12" ref-type="bibr">12</xref>). The high TMB was associated with substantial structural variation, without recurrent gene fusions.</p>
        <p>Alexandrov et al. (<xref rid="B52" ref-type="bibr">52</xref>) detailed patterns of mutational signatures in 23,829 tumor samples (1,965 WGS) from the Pan Cancer Analysis of Whole Genomes (PCAWG) datasets including 17 small ID signatures, expanded to 18 in COSMIC version 3.2 (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://cancer.sanger.ac.uk">https://cancer.sanger.ac.uk</uri>) (<xref rid="B53" ref-type="bibr">53</xref>). However, no cutaneous SCCs (primary or metastatic) are included in this dataset. We identified the predominance of ID signatures 8, 9, and 13 (100% of samples effected) in our 25 metastatic CSCC samples. ID8 is thought to be both related to double-strand DNA break repair dysfunction and to age-related changes. Melanoma is the only other cancer type reported to have a predominant ID 13 signature (<xref rid="B52" ref-type="bibr">52</xref>). Our data also provide evidence of concomitance of ID13 with SBS 7a and 7b (<xref rid="f1" ref-type="fig"><bold>Figures 1C, D</bold></xref>; <xref rid="SM1" ref-type="supplementary-material"><bold>Supplementary Table S2</bold></xref>) in keeping with a UV-mediated mechanism for this signature. While we found ID9 to be a dominant indel signature in CSCC, it is rare in melanoma (2/104) but predominant in soft tissue sarcoma (<xref rid="B52" ref-type="bibr">52</xref>). The mechanism of ID9 is unclear, but this departure from what is found in melanoma clearly shows some point of difference in these UV-induced skin cancers. When comparing the TMB associated with ID9 signature among different cancers, the dominance in CSCC is clearly visible (<xref rid="f7" ref-type="fig"><bold>Figure 7</bold></xref>). One case of SBS32 is due to azathioprine exposure.</p>
        <fig position="float" id="f7" orientation="portrait">
          <label>Figure 7</label>
          <caption>
            <p>Comparison plot of ID9 mutations for various cancers. CSCC shows the highest ID9 mutations per Mb. The bottom x-axis represents the cancer types, and the upper x-axis shows the number of samples measured for specific cancer types. y-Axis indicates the number of mutations per Mb. Data for other cancers was obtained from ID9 signature details from COSMIC V3.2 and compared with CSCC data. CSCC data is calculated as ID9 signature score/3100 (coverage for hg38 genome).</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fonc-12-919118-g007.jpg"/>
        </fig>
        <p>We identified substantial somatic variation within the 3′UTR region of <italic toggle="yes">EVC</italic>, <italic toggle="yes">LUM</italic>, and <italic toggle="yes">PPP1R1A. EVC</italic> affects ciliary Hedgehog (Hh) regulation. Aberrant overexpression of <italic toggle="yes">EVC</italic> (and upregulation of Hh) has been reported in adult T-cell leukemia as a result of epigenetic modulation (<xref rid="B54" ref-type="bibr">54</xref>). The expression of <italic toggle="yes">EVC</italic> is reduced in nodal deposits of metastatic breast cancer compared with primary breast cancer, suggesting a role in the metastatic process (<xref rid="B55" ref-type="bibr">55</xref>). <italic toggle="yes">LUM</italic> is a major keratan sulfate proteoglycan that plays a role in collagen fibril organization, circumferential growth, epithelial cell migration, and tissue repair, among many other functions (<xref rid="B56" ref-type="bibr">56</xref>). <italic toggle="yes">PPP1R1A</italic> encodes a protein phosphatase inhibitor, which appears to have a variable but significant role in the metastatic process. For example, it is overexpressed in Ewing sarcoma and has been proposed as a driver of metastasis (<xref rid="B57" ref-type="bibr">57</xref>). Conversely, levels of <italic toggle="yes">PPP1R1A</italic> were reduced in breast cancer when compared to adjacent non-diseased breast tissue (<xref rid="B58" ref-type="bibr">58</xref>). Within our cohort, we observed a unique recurrent missense mutation in the 3′UTR of <italic toggle="yes">PPP1R1A</italic> in five samples.</p>
        <p>
<italic toggle="yes">LINC01003</italic> was the most mutated lncRNA in our cohort (64% of samples). In multiple myeloma, <italic toggle="yes">LINC01003</italic> behaves as a tumor suppressor genomic element. Upregulation suppresses multiple myeloma by repressing cell viability and adhesion and promoting apoptosis. This effect is <italic toggle="yes">via</italic> its sponge effect on miR-33a-5p and its target <italic toggle="yes">PIM1</italic> (<xref rid="B59" ref-type="bibr">59</xref>).</p>
        <p>As has been frequently reported for CSCC (<xref rid="B5" ref-type="bibr">5</xref>) (<xref rid="SM1" ref-type="supplementary-material"><bold>Supplementary Figure S1</bold></xref>), <italic toggle="yes">TP53</italic> and <italic toggle="yes">CDKN2A</italic> were also the most recurrently altered genes in our cohort. Loss of function mutations within <italic toggle="yes">TP53</italic> and <italic toggle="yes">CDKN2A</italic> are well known to adversely impact cell cycle pathway control and DNA repair mechanisms, thus increasing TMB. Furthermore, <italic toggle="yes">TP53</italic> and <italic toggle="yes">CDKN2A</italic> mutations in other squamous cell carcinomas such as NSCLC (<xref rid="B60" ref-type="bibr">60</xref>) and HNSCC (<xref rid="B61" ref-type="bibr">61</xref>) correlates with response to immune checkpoint inhibitors. With <italic toggle="yes">TP53</italic> and <italic toggle="yes">CDKN2A</italic> as driver genes in our study, the generally high response rates to immune checkpoint inhibitors in advanced and metastatic CSCC is not surprising. Kilnakis et al. (<xref rid="B62" ref-type="bibr">62</xref>) describe a pattern of <italic toggle="yes">TP53</italic> mutation that differed between primary and metastatic disease in head and neck (mucosal) SCC. They found an overall lower rate of mutations in metastatic tumors but a higher concentration of missense mutations in the DNA binding regions of the gene. However, Yilmaz et al. (<xref rid="B17" ref-type="bibr">17</xref>) reported a significantly higher <italic toggle="yes">TP53</italic> mutation frequency in metastatic (85%) compared to primary CSCC (corrected p-value &lt;0.002). Our cBioPortal dataset analysis indicated no difference in variant frequency for <italic toggle="yes">TP53</italic> between primary and metastatic CSCC (refer to <xref rid="SM1" ref-type="supplementary-material"><bold>Supplementary Figure S1</bold></xref>), suggesting retention in metastatic tumors.</p>
        <p>Of note in our study was the absence of significant or recurrent SNVs affecting <italic toggle="yes">NOTCH1/2</italic>. Inman et al. (<xref rid="B15" ref-type="bibr">15</xref>) compared well-differentiated to moderately and poorly differentiated primary CSCC and identified <italic toggle="yes">NOTCH1</italic>, <italic toggle="yes">NOTCH2</italic>, <italic toggle="yes">TP53</italic>, and <italic toggle="yes">CDKN2A</italic> as the most commonly mutated genes, with <italic toggle="yes">ATP1A1</italic>, <italic toggle="yes">HERC6</italic>, <italic toggle="yes">MAPK1P1L</italic>, <italic toggle="yes">GRHL2</italic>, <italic toggle="yes">TRAPPC9</italic>, <italic toggle="yes">FLNB</italic>, and <italic toggle="yes">MAP3K9</italic> identified as common early events in primary CSCC. Within this group, <italic toggle="yes">GRHL2</italic> was associated with less well-differentiated tumors including those with a worse prognosis. In our cohort, only a single splice variant in <italic toggle="yes">GRHL2</italic> was identified, suggesting that its role in metastatic disease is limited.</p>
        <p>
<italic toggle="yes">C9</italic> (encodes complement component 9) was also identified as a potential driver gene by three driver identification tools, with SNVs identified in 52% of the samples in our cohort. C9 is part of the membrane attack complex (MAC) and has been shown to modulate cellular behavior in the tumor microenvironment (TME) (<xref rid="B63" ref-type="bibr">63</xref>). Since the TME plays a crucial role in tumorigenesis, progression, metastasis, and recurrence, C9 might have significant potential in CSCC progression to metastasis. Various other components of the complement system have been linked to CSCC progression and immunosuppression and implicated as potential therapeutic targets (<xref rid="B64" ref-type="bibr">64</xref>–<xref rid="B66" ref-type="bibr">66</xref>). With respect to <italic toggle="yes">C9</italic> specifically, it appears to be recurrently mutated in CSCC specimens (31% in primary and 10% in metastatic CSCC) as identified in the cBioPortal database (<xref rid="SM1" ref-type="supplementary-material"><bold>Supplementary Figure S1</bold></xref>). and high expression levels have been proposed as a potential biomarker for the detection of gastric cancers (<xref rid="B67" ref-type="bibr">67</xref>) (<xref rid="B68" ref-type="bibr">68</xref>). Furthermore, the restrained expression of <italic toggle="yes">C9</italic> in tumor-associated macrophages promotes non-small cell lung cancer progression (<xref rid="B69" ref-type="bibr">69</xref>).</p>
        <p>Apart from <italic toggle="yes">TP53</italic>, <italic toggle="yes">CDKN2A</italic>, and <italic toggle="yes">C9</italic>, we identified nine other potential driver genes with the most recurrently mutated gene being <italic toggle="yes">KHDRBS2</italic> (48% of cohort) with various impacts, including stop gained, complex, and synonymous types apart from missense variant across the cohort. In the cBioPortal database, this gene is mutated in 20% of metastatic CSCC specimens (<xref rid="SM1" ref-type="supplementary-material"><bold>Supplementary Figure S1</bold></xref>), suggesting that it is a reasonably recurrently mutated gene in this disease.</p>
        <p>A comparison of mutational frequency of primary and metastatic CSCC on the cBioPortal data suggests the potential of <italic toggle="yes">COLEC12</italic> (primary=25%; metastatic=60%) and <italic toggle="yes">SLC22A6</italic> (primary=16%; metastatic=30%) as drivers in metastatic CSCC (<xref rid="SM1" ref-type="supplementary-material"><bold>Supplementary Figure S1</bold></xref>). Both <italic toggle="yes">COLEC12</italic> and <italic toggle="yes">SLC33A6</italic> are mutated in 44% of the samples in our cohort, and many of them are high-impact SNVs. <italic toggle="yes">COLEC12</italic> is involved in leukocyte recruitment and cancer metastasis (<xref rid="B70" ref-type="bibr">70</xref>) and regulates the apoptosis of osteosarcoma (<xref rid="B70" ref-type="bibr">70</xref>). Moreover, <italic toggle="yes">COLEC12</italic> is a potential biomarker of anaplastic thyroid cancer (ATC) (<xref rid="B71" ref-type="bibr">71</xref>). In one study of cancerous gastric stromal cells (GSCs), the role of <italic toggle="yes">COLEC12</italic> is found in mediating the crosstalk between GSCs and dendritic cells (DCs) (<xref rid="B72" ref-type="bibr">72</xref>). On the other hand, <italic toggle="yes">SLC22A6</italic> is known as an organic anion transporter 1 (<italic toggle="yes">OAT1</italic>). Expression and function alterations of <italic toggle="yes">OAT1</italic> play an essential role in therapeutic efficacy and the toxicity of many drugs, such as for anti-cancer drugs methotrexate, bleomycin, and cisplatin-related toxicity (<xref rid="B73" ref-type="bibr">73</xref>–<xref rid="B75" ref-type="bibr">75</xref>). <italic toggle="yes">OAT1</italic> variation associated with cardiotoxicity in pediatric acute lymphoblastic leukemia and osteosarcoma (<xref rid="B76" ref-type="bibr">76</xref>). Furthermore, the role of <italic toggle="yes">OAT1</italic> in breast cancer metastasis has been reported (<xref rid="B77" ref-type="bibr">77</xref>). Important cancer-related roles of the other potential CSCC drivers are reported in <xref rid="SM1" ref-type="supplementary-material"><bold>Supplementary Table S7</bold></xref>.</p>
        <p>Loss of <italic toggle="yes">PTPRD</italic> was the most prominent copy number alteration in our 25 samples. <italic toggle="yes">PTPRD</italic> encodes protein tyrosine phosphatase receptor D, which belongs to a family of receptors whose action opposes that of the tyrosine kinases, which are central to cell growth and differentiation and oncogenic transformation. Large-scale genomic events impacting <italic toggle="yes">CDKN2A</italic> can also affect <italic toggle="yes">PTPRD</italic> due to their proximity on chr9 (<xref rid="B78" ref-type="bibr">78</xref>). In head and neck SCC, <italic toggle="yes">PTPRD</italic> inactivation significantly increases <italic toggle="yes">STAT3</italic> hyperactivation, which was associated with decreased survival and resistance to epidermal growth factor receptor (EGFR)-targeted therapy (<xref rid="B79" ref-type="bibr">79</xref>). <italic toggle="yes">PTPRD</italic> has been implicated as a tumor suppressor in several cancers with inactivating somatic variants found in &gt;50% of GBM and between 10% and 20% of head and neck mucosal SCC (HNSCC) (<xref rid="B80" ref-type="bibr">80</xref>). Lambert et al. (<xref rid="B45" ref-type="bibr">45</xref>) described deletions of <italic toggle="yes">PTPRD</italic> in 37% of metastatic primary CSCC and metastases. In addition, some of their cases also displayed a variant in the minor allele concordant with the deletion leading to a LOH event. It is thus possible that <italic toggle="yes">PTPRD</italic> plays a tumor suppressor role in preventing metastatic CSCC.</p>
        <p>There were no recurrently amplified genes except for <italic toggle="yes">CALR</italic>, <italic toggle="yes">CCND1</italic>, and <italic toggle="yes">FGF3</italic>, which were each only amplified in 2/25 samples (<xref rid="T3" ref-type="table"><bold>Table 3</bold></xref>). <italic toggle="yes">CALR</italic> encodes a ubiquitous endoplasmic-reticulum-bound calcium receptor (<xref rid="B81" ref-type="bibr">81</xref>). Cellular stress can move <italic toggle="yes">CALR</italic> fragments to the plasma membrane from the ER and influence immune recognition of cancer cells. Recent analysis of <italic toggle="yes">CALR</italic> fragments in myeloproliferative disease suggests an immunosuppressive influence of extracellular <italic toggle="yes">CALR</italic> (<xref rid="B82" ref-type="bibr">82</xref>). Cyclin D1 (<italic toggle="yes">CCND1</italic>) amplification is associated with nodal metastasis and worse survival in oral SCC (<xref rid="B83" ref-type="bibr">83</xref>). In a review of <italic toggle="yes">CCND1</italic> copy number variation in metastatic non-cutaneous melanoma, amplification was prominent in those patients whose disease did not respond to immune checkpoint inhibition (<xref rid="B84" ref-type="bibr">84</xref>). <italic toggle="yes">FGF3</italic> amplification is more common in metastatic breast cancer than primary tumors (<xref rid="B85" ref-type="bibr">85</xref>). Targetable <italic toggle="yes">FGF3</italic> amplification was associated with a poorer prognosis and lung metastasis in hepatocellular carcinoma (<xref rid="B86" ref-type="bibr">86</xref>). This amplification was seen in only 2% of total HCC but was most common in those cancers showing rapid response to sorafenib.</p>
        <p>With respect to enrichment of driver gene alterations observed in our samples, dysregulation of the cell cycle pathway appears to be the central genomic theme of metastatic CSCC supported mainly by <italic toggle="yes">TP53</italic> and <italic toggle="yes">CDKN2A</italic>. <italic toggle="yes">CDKN2A</italic> encodes the CDK inhibitor p16<sup>INK4a</sup>. This inhibitor is an important controller of the activity of CDKs and progression from G1 to mitosis in the cell cycle. Inactivating mutations in <italic toggle="yes">CDKN2A</italic> with effects on p16<sup>INK4a</sup> regulatory functions uncouple cell cycle control to promote cell survival and tumorigenesis (<xref rid="B87" ref-type="bibr">87</xref>). CDK4/6 inhibitors such as palbociclib, which has demonstrated response in metastatic breast cancer, may likewise be a potential therapeutic strategy for metastatic CSCC. Interaction between <italic toggle="yes">CDKN2A</italic> and <italic toggle="yes">TP53</italic> through <italic toggle="yes">MDM2</italic> and its regulation by ARF (also encoded by <italic toggle="yes">CDKN2A</italic>) further disable cell cycle and apoptotic pathways (GO: molecular function enrichment shows MDM2/MDM4 family protein binding). The pro-tumorigenic functions of the p53-MDM2-ARF network is gaining traction as a target for novel therapeutic strategies (<xref rid="B88" ref-type="bibr">88</xref>), which could also be applied to CSCC.</p>
        <p>The cellular process defined by the term “TGF beta regulation of extra cellular matrix” was also significantly enriched showing a role for <italic toggle="yes">LUM</italic>, <italic toggle="yes">CDHR5</italic>, <italic toggle="yes">COLEC12</italic>, and <italic toggle="yes">CDKN2A</italic> in this process (<xref rid="f5" ref-type="fig"><bold>Figure 5A</bold></xref>). Compartment enrichment analysis found that these genetically altered genes are part of the extracellular compartment. Our previous differential expression study confirmed that TGFβ and the extracellular matrix component have an important role in metastatic CSCC (<xref rid="B89" ref-type="bibr">89</xref>). Inactivation of cell cycle control (through <italic toggle="yes">CDKN2A</italic> alterations for example) would allow tumor cells to escape from TGFβ-mediated suppressive effects. As loss of this growth-inhibitory response occurs at a level downstream of the core TGFβ signaling pathway, TGFβ then switches to a tumor-progression factor promoting epithelial-to-mesenchymal transition while inhibiting proliferation, differentiation, and the antitumor activity of multiple immune cells (<xref rid="B90" ref-type="bibr">90</xref>). As TGFβ receptor inhibition in combination with gemcitabine or immunotherapy is showing promise in other cancers (<xref rid="B91" ref-type="bibr">91</xref>, <xref rid="B92" ref-type="bibr">92</xref>), this approach may also be applicable to metastatic CSCC.</p>
        <p>Finally, <italic toggle="yes">miR-331-5p</italic> shows promise as a potentiator of CSCC drivers. <italic toggle="yes">miR-331-5p</italic> downregulation contributes to chemotherapy resistance/relapse in leukemia (<xref rid="B93" ref-type="bibr">93</xref>), and it inhibits proliferation by targeting PI3K/Akt and ERK1/2 pathways in colorectal cancer (<xref rid="B94" ref-type="bibr">94</xref>).</p>
      </sec>
      <sec id="s5">
        <title>Conclusion</title>
        <p>WGS provides insight into the unparalleled burden of mutation within metastatic CSCC, and our study has provided a deeper understanding of the genomic complexity of this disease. The functional impact of the varied and complex genetic alterations observed in metastatic CSCC should be validated in the future in confirmatory studies comparing whole genomes of non-metastatic primary tumors to metastatic tumors. This knowledge would significantly contribute to the identification of biomarkers in primary CSCC for predicting metastasis.</p>
      </sec>
      <sec sec-type="data-availability" id="s6">
        <title>Data availability statement</title>
        <p>The original contributions presented in the study are included in the article/<xref rid="SM1" ref-type="supplementary-material"><bold>Supplementary Materials</bold></xref>. The variant call format files have been deposited at the European Genome-Phenome Archive, which is hosted by the EMBL-European Bioinformatics Institute and the Center for Genomic Regulation, under accession number EGAS00001006378.</p>
      </sec>
      <sec sec-type="ethics-statement" id="s7">
        <title>Ethics statement</title>
        <p>This study was undertaken with Institutional Human Research Ethics approval (UOW/ISLHD HREC14/397). The patients/participants provided their written informed consent to participate in this study.</p>
      </sec>
      <sec sec-type="author-contributions" id="s8">
        <title>Author contributions</title>
        <p>AT and DS performed the bioinformatics analyses. BA and NGI conceived the idea and assisted in bioinformatics analyses. BA, AT, and MR drafted manuscript versions. BA, MR, RG, and JC obtained funding for the project. BA, JC, JM, SM, SC, and RG collated samples and/or clinical data. JP and EM completed tissue processing. All authors reviewed and edited the manuscript. All authors contributed to the article and approved the submitted version.</p>
      </sec>
      <sec sec-type="funding-information" id="s9">
        <title>Funding</title>
        <p>This work was funded by the Illawarra Cancer Carers, The Head and Neck Research Fund, Royal Prince Alfred Institute of Academic Surgery, The Cancer Institute NSW translational program grant, Chris O’Brien Lifehouse, National Health and Medical Research Council Project Grant APP1181179, and Tour de Cure. The authors would like to acknowledge A/Prof Carsten Palme and Dr. Kerwin Shannon for suggestions and National Computational Infrastructure (NCI-GADI) and Sydney Informatics Hub for computational services.</p>
      </sec>
      <sec sec-type="COI-statement" id="s10">
        <title>Conflict of interest</title>
        <p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
      </sec>
      <sec sec-type="disclaimer" id="s11">
        <title>Publisher’s note</title>
        <p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
      </sec>
    </body>
    <back>
      <fn-group>
        <fn id="fn1">
          <label>1</label>
          <p>Staging according to AJCC 8th edition. </p>
        </fn>
        <fn id="fn2">
          <label>2</label>
          <p>Lymph node ratio (Number of positive nodes/total nodes harvested).</p>
        </fn>
        <fn id="fn3">
          <label>3</label>
          <p>Grade 1: well differentiated; Grade 2: moderately differentiated; Grade 3: poorly differentiated.</p>
        </fn>
      </fn-group>
      <sec sec-type="supplementary-material" id="s12">
        <title>Supplementary material</title>
        <p>The Supplementary Material for this article can be found online at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.frontiersin.org/articles/10.3389/fonc.2022.919118/full#supplementary-material" ext-link-type="uri">https://www.frontiersin.org/articles/10.3389/fonc.2022.919118/full#supplementary-material</ext-link>
</p>
        <supplementary-material id="SM1" position="float" content-type="local-data" orientation="portrait">
          <media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="DataSheet_1.zip" position="float" orientation="portrait">
            <caption>
              <p>Click here for additional data file.</p>
            </caption>
          </media>
        </supplementary-material>
        <supplementary-material id="SF1" position="float" content-type="local-data" orientation="portrait">
          <media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Image_1.pdf" position="float" orientation="portrait">
            <caption>
              <p>Click here for additional data file.</p>
            </caption>
          </media>
        </supplementary-material>
        <supplementary-material id="ST1" position="float" content-type="local-data" orientation="portrait">
          <media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Table_1.xlsx" position="float" orientation="portrait">
            <caption>
              <p>Click here for additional data file.</p>
            </caption>
          </media>
        </supplementary-material>
        <supplementary-material id="ST2" position="float" content-type="local-data" orientation="portrait">
          <media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Table_2.xls" position="float" orientation="portrait">
            <caption>
              <p>Click here for additional data file.</p>
            </caption>
          </media>
        </supplementary-material>
        <supplementary-material id="ST3" position="float" content-type="local-data" orientation="portrait">
          <media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Table_3.xlsx" position="float" orientation="portrait">
            <caption>
              <p>Click here for additional data file.</p>
            </caption>
          </media>
        </supplementary-material>
        <supplementary-material id="ST4" position="float" content-type="local-data" orientation="portrait">
          <media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Table_4.xls" position="float" orientation="portrait">
            <caption>
              <p>Click here for additional data file.</p>
            </caption>
          </media>
        </supplementary-material>
        <supplementary-material id="ST5" position="float" content-type="local-data" orientation="portrait">
          <media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Table_5.xlsx" position="float" orientation="portrait">
            <caption>
              <p>Click here for additional data file.</p>
            </caption>
          </media>
        </supplementary-material>
        <supplementary-material id="ST6" position="float" content-type="local-data" orientation="portrait">
          <media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Table_6.xls" position="float" orientation="portrait">
            <caption>
              <p>Click here for additional data file.</p>
            </caption>
          </media>
        </supplementary-material>
        <supplementary-material id="ST7" position="float" content-type="local-data" orientation="portrait">
          <media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Table_7.docx" position="float" orientation="portrait">
            <caption>
              <p>Click here for additional data file.</p>
            </caption>
          </media>
        </supplementary-material>
      </sec>
      <ref-list>
        <title>References</title>
        <ref id="B1">
          <label>1</label>
          <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rogers</surname><given-names>HW</given-names></name><name name-style="western"><surname>Weinstock</surname><given-names>MA</given-names></name><name name-style="western"><surname>Feldman</surname><given-names>SR</given-names></name><name name-style="western"><surname>Coldiron</surname><given-names>BM</given-names></name></person-group>. <article-title>Incidence estimate of nonmelanoma skin cancer (Keratinocyte carcinomas) in the US population, 2012</article-title>. <source>JAMA Dermatol</source> (<year>2015</year>) <volume>151</volume>(<issue>10</issue>):<page-range>1081–6</page-range>. doi: <pub-id pub-id-type="doi">10.1001/jamadermatol.2015.1187</pub-id><pub-id pub-id-type="pmid">25928283</pub-id></mixed-citation>
        </ref>
        <ref id="B2">
          <label>2</label>
          <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Waldman</surname><given-names>A</given-names></name><name name-style="western"><surname>Schmults</surname><given-names>C</given-names></name></person-group>. <article-title>Cutaneous squamous cell carcinoma</article-title>. <source>Hematol Oncol Clin North Am</source> (<year>2019</year>) <volume>33</volume>(<issue>1</issue>):<fpage>1</fpage>–<lpage>12</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.hoc.2018.08.001</pub-id><pub-id pub-id-type="pmid">30497667</pub-id></mixed-citation>
        </ref>
        <ref id="B3">
          <label>3</label>
          <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Venables</surname><given-names>ZC</given-names></name><name name-style="western"><surname>Autier</surname><given-names>P</given-names></name><name name-style="western"><surname>Nijsten</surname><given-names>T</given-names></name><name name-style="western"><surname>Wong</surname><given-names>KF</given-names></name><name name-style="western"><surname>Langan</surname><given-names>SM</given-names></name><name name-style="western"><surname>Rous</surname><given-names>B</given-names></name><etal/></person-group>. <article-title>Nationwide incidence of metastatic cutaneous squamous cell carcinoma in England</article-title>. <source>JAMA Dermatol</source> (<year>2019</year>) <volume>155</volume>(<issue>3</issue>):<fpage>298</fpage>–<lpage>306</lpage>. doi: <pub-id pub-id-type="doi">10.1001/jamadermatol.2018.4219</pub-id><pub-id pub-id-type="pmid">30484823</pub-id><pub-id pub-id-type="pmcid">PMC6521686</pub-id></mixed-citation>
        </ref>
        <ref id="B4">
          <label>4</label>
          <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Forest</surname><given-names>VI</given-names></name><name name-style="western"><surname>Clark</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Veness</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Milross</surname><given-names>C</given-names></name></person-group>. <article-title>N1S3: A revised staging system for head and neck cutaneous squamous cell carcinoma with lymph node metastases: Results of 2 Australian cancer centers</article-title>. <source>Cancer: Interdiscip Int J Am Cancer Soc</source> (<year>2010</year>) <volume>116</volume>(<issue>5</issue>):<page-range>1298–304</page-range>. doi: <pub-id pub-id-type="doi">10.1002/cncr.24855</pub-id><pub-id pub-id-type="pmid">20052712</pub-id></mixed-citation>
        </ref>
        <ref id="B5">
          <label>5</label>
          <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ashford</surname><given-names>BG</given-names></name><name name-style="western"><surname>Clark</surname><given-names>J</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>R</given-names></name><name name-style="western"><surname>Iyer</surname><given-names>NG</given-names></name><name name-style="western"><surname>Yu</surname><given-names>B</given-names></name><name name-style="western"><surname>Ranson</surname><given-names>M</given-names></name></person-group>. <article-title>Reviewing the genetic alterations in high-risk cutaneous squamous cell carcinoma: A search for prognostic markers and therapeutic targets</article-title>. <source>Head Neck</source> (<year>2017</year>) <volume>39</volume>(<issue>7</issue>):<page-range>1462–9</page-range>. doi: <pub-id pub-id-type="doi">10.1002/hed.24765</pub-id><pub-id pub-id-type="pmid">28370784</pub-id></mixed-citation>
        </ref>
        <ref id="B6">
          <label>6</label>
          <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mooney</surname><given-names>CP</given-names></name><name name-style="western"><surname>Clark</surname><given-names>JR</given-names></name><name name-style="western"><surname>Shannon</surname><given-names>K</given-names></name><name name-style="western"><surname>Palme</surname><given-names>CE</given-names></name><name name-style="western"><surname>Ebrahimi</surname><given-names>A</given-names></name><name name-style="western"><surname>Gao</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>The significance of regional metastasis location in head and neck cutaneous squamous cell carcinoma</article-title>. <source>Head Neck</source> (<year>2021</year>) <volume>43</volume>(<issue>9</issue>):<page-range>2705–11</page-range>. doi: <pub-id pub-id-type="doi">10.1002/hed.26744</pub-id><pub-id pub-id-type="pmid">34019319</pub-id></mixed-citation>
        </ref>
        <ref id="B7">
          <label>7</label>
          <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Veness</surname><given-names>MJ</given-names></name></person-group>. <article-title>Treatment recommendations in patients diagnosed with high-risk cutaneous squamous cell carcinoma</article-title>. <source>Australas Radiol</source> (<year>2005</year>) <volume>49</volume>(<issue>5</issue>):<page-range>365–76</page-range>. doi: <pub-id pub-id-type="doi">10.1111/j.1440-1673.2005.01496.x</pub-id><pub-id pub-id-type="pmid">16174174</pub-id></mixed-citation>
        </ref>
        <ref id="B8">
          <label>8</label>
          <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Garcia-Foncillas</surname><given-names>J</given-names></name><name name-style="western"><surname>Tejera-Vaquerizo</surname><given-names>A</given-names></name><name name-style="western"><surname>Sanmartin</surname><given-names>O</given-names></name><name name-style="western"><surname>Rojo</surname><given-names>F</given-names></name><name name-style="western"><surname>Mestre</surname><given-names>J</given-names></name><name name-style="western"><surname>Martin</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Update on management recommendations for advanced cutaneous squamous cell carcinoma</article-title>. <source>Cancers (Basel)</source> (<year>2022</year>) <volume>14</volume>(<issue>3</issue>):<fpage>629</fpage>. doi: <pub-id pub-id-type="doi">10.3390/cancers14030629</pub-id><pub-id pub-id-type="pmid">35158897</pub-id><pub-id pub-id-type="pmcid">PMC8833756</pub-id></mixed-citation>
        </ref>
        <ref id="B9">
          <label>9</label>
          <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stanganelli</surname><given-names>I</given-names></name><name name-style="western"><surname>Spagnolo</surname><given-names>F</given-names></name><name name-style="western"><surname>Argenziano</surname><given-names>G</given-names></name><name name-style="western"><surname>Ascierto</surname><given-names>PA</given-names></name><name name-style="western"><surname>Bassetto</surname><given-names>F</given-names></name><name name-style="western"><surname>Bossi</surname><given-names>P</given-names></name><etal/></person-group>. <article-title>The multidisciplinary management of cutaneous squamous cell carcinoma: A comprehensive review and clinical recommendations by a panel of experts</article-title>. <source>Cancers (Basel)</source> (<year>2022</year>) <volume>14</volume>(<issue>2</issue>):<fpage>377</fpage>. doi: <pub-id pub-id-type="doi">10.3390/cancers14020377</pub-id><pub-id pub-id-type="pmid">35053539</pub-id><pub-id pub-id-type="pmcid">PMC8773547</pub-id></mixed-citation>
        </ref>
        <ref id="B10">
          <label>10</label>
          <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Migden</surname><given-names>MR</given-names></name><name name-style="western"><surname>Rischin</surname><given-names>D</given-names></name><name name-style="western"><surname>Schmults</surname><given-names>CD</given-names></name><name name-style="western"><surname>Guminski</surname><given-names>A</given-names></name><name name-style="western"><surname>Hauschild</surname><given-names>A</given-names></name><name name-style="western"><surname>Lewis</surname><given-names>KD</given-names></name><etal/></person-group>. <article-title>PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma</article-title>. <source>N Engl J Med</source> (<year>2018</year>) <volume>379</volume>(<issue>4</issue>):<page-range>341–51</page-range>. doi: <pub-id pub-id-type="doi">10.1056/NEJMoa1805131</pub-id><pub-id pub-id-type="pmid">29863979</pub-id></mixed-citation>
        </ref>
        <ref id="B11">
          <label>11</label>
          <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aboul-Fettouh</surname><given-names>N</given-names></name><name name-style="western"><surname>Morse</surname><given-names>D</given-names></name><name name-style="western"><surname>Patel</surname><given-names>J</given-names></name><name name-style="western"><surname>Migden</surname><given-names>MR</given-names></name></person-group>. <article-title>Immunotherapy and systemic treatment of cutaneous squamous cell carcinoma</article-title>. <source>Dermatol Pract Concept</source> (<year>2021</year>) <volume>11</volume>(<issue>Suppl 2</issue>):<elocation-id>e2021169S</elocation-id>. doi: <pub-id pub-id-type="doi">10.5826/dpc.11S2a169S</pub-id><pub-id pub-id-type="pmid">34877077</pub-id><pub-id pub-id-type="pmcid">PMC8609954</pub-id></mixed-citation>
        </ref>
        <ref id="B12">
          <label>12</label>
          <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mueller</surname><given-names>SA</given-names></name><name name-style="western"><surname>Gauthier</surname><given-names>MA</given-names></name><name name-style="western"><surname>Ashford</surname><given-names>B</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>R</given-names></name><name name-style="western"><surname>Gayevskiy</surname><given-names>V</given-names></name><name name-style="western"><surname>Ch'ng</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Mutational patterns in metastatic cutaneous squamous cell carcinoma</article-title>. <source>J Invest Dermatol</source> (<year>2019</year>) <volume>139</volume>(<issue>7</issue>):<fpage>1449</fpage>–<lpage>1458 e1</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jid.2019.01.008</pub-id><pub-id pub-id-type="pmid">30684551</pub-id></mixed-citation>
        </ref>
        <ref id="B13">
          <label>13</label>
          <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Perry</surname><given-names>J</given-names></name><name name-style="western"><surname>Ashford</surname><given-names>B</given-names></name><name name-style="western"><surname>Thind</surname><given-names>AS</given-names></name><name name-style="western"><surname>Gauthier</surname><given-names>M-E</given-names></name><name name-style="western"><surname>Minaei</surname><given-names>E</given-names></name><name name-style="western"><surname>Major</surname><given-names>G</given-names></name><etal/></person-group>. <article-title>Comprehensive mutational and phenotypic characterization of new metastatic cutaneous squamous cell carcinoma cell lines reveal novel drug susceptibilities</article-title>. <source>Int J Mol Sci</source> (<year>2020</year>) <volume>21</volume>(<issue>24</issue>):<fpage>9536</fpage>. doi: <pub-id pub-id-type="doi">10.3390/ijms21249536</pub-id><pub-id pub-id-type="pmcid">PMC7765308</pub-id><pub-id pub-id-type="pmid">33333825</pub-id></mixed-citation>
        </ref>
        <ref id="B14">
          <label>14</label>
          <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zilberg</surname><given-names>C</given-names></name><name name-style="western"><surname>Lee</surname><given-names>MW</given-names></name><name name-style="western"><surname>Yu</surname><given-names>B</given-names></name><name name-style="western"><surname>Ashford</surname><given-names>B</given-names></name><name name-style="western"><surname>Kraitsek</surname><given-names>S</given-names></name><name name-style="western"><surname>Ranson</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Analysis of clinically relevant somatic mutations in high-risk head and neck cutaneous squamous cell carcinoma</article-title>. <source>Modern Pathol</source> (<year>2018</year>) <volume>31</volume>(<issue>2</issue>):<page-range>275–87</page-range>. doi: <pub-id pub-id-type="doi">10.1038/modpathol.2017.128</pub-id><pub-id pub-id-type="pmid">28984303</pub-id></mixed-citation>
        </ref>
        <ref id="B15">
          <label>15</label>
          <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Inman</surname><given-names>GJ</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name><name name-style="western"><surname>Nagano</surname><given-names>A</given-names></name><name name-style="western"><surname>Alexandrov</surname><given-names>LB</given-names></name><name name-style="western"><surname>Purdie</surname><given-names>KJ</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>RGc</given-names></name><etal/></person-group>. <article-title>The genomic landscape of cutaneous SCC reveals drivers and a novel azathioprine associated mutational signature</article-title>. <source>Nat Commun</source> (<year>2018</year>) <volume>9</volume>(<issue>1</issue>):<fpage>3667</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41467-018-06027-1</pub-id><pub-id pub-id-type="pmid">30202019</pub-id><pub-id pub-id-type="pmcid">PMC6131170</pub-id></mixed-citation>
        </ref>
        <ref id="B16">
          <label>16</label>
          <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Al-Rohil</surname><given-names>RN</given-names></name><name name-style="western"><surname>Tarasen</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Carlson</surname><given-names>JA</given-names></name><name name-style="western"><surname>Wang</surname><given-names>K</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>A</given-names></name><name name-style="western"><surname>Yelensky</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Evaluation of 122 advanced-stage cutaneous squamous cell carcinomas by comprehensive genomic profiling opens the door for new routes to targeted therapies</article-title>. <source>Cancer</source> (<year>2016</year>) <volume>122</volume>(<issue>2</issue>):<page-range>249–57</page-range>. doi: <pub-id pub-id-type="doi">10.1002/cncr.29738</pub-id><pub-id pub-id-type="pmid">26479420</pub-id></mixed-citation>
        </ref>
        <ref id="B17">
          <label>17</label>
          <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yilmaz</surname><given-names>AS</given-names></name><name name-style="western"><surname>Ozer</surname><given-names>HG</given-names></name><name name-style="western"><surname>Gillespie</surname><given-names>JL</given-names></name><name name-style="western"><surname>Allain</surname><given-names>DC</given-names></name><name name-style="western"><surname>Bernhardt</surname><given-names>MN</given-names></name><name name-style="western"><surname>Furlan</surname><given-names>KC</given-names></name><etal/></person-group>. <article-title>Differential mutation frequencies in metastatic cutaneous squamous cell carcinomas versus primary tumors</article-title>. <source>Cancer</source> (<year>2017</year>) <volume>123</volume>(<issue>7</issue>):<page-range>1184–93</page-range>. doi: <pub-id pub-id-type="doi">10.1002/cncr.30459</pub-id><pub-id pub-id-type="pmcid">PMC5360561</pub-id><pub-id pub-id-type="pmid">27906449</pub-id></mixed-citation>
        </ref>
        <ref id="B18">
          <label>18</label>
          <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zehir</surname><given-names>A</given-names></name><name name-style="western"><surname>Benayed</surname><given-names>R</given-names></name><name name-style="western"><surname>Shah</surname><given-names>RH</given-names></name><name name-style="western"><surname>Syed</surname><given-names>A</given-names></name><name name-style="western"><surname>Middha</surname><given-names>S</given-names></name><name name-style="western"><surname>Kim</surname><given-names>HR</given-names></name><etal/></person-group>. <article-title>Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients</article-title>. <source>Nat Med</source> (<year>2017</year>) <volume>23</volume>(<issue>6</issue>):<page-range>703–13</page-range>. doi: <pub-id pub-id-type="doi">10.1038/nm.4333</pub-id><pub-id pub-id-type="pmcid">PMC5461196</pub-id><pub-id pub-id-type="pmid">28481359</pub-id></mixed-citation>
        </ref>
        <ref id="B19">
          <label>19</label>
          <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>YY</given-names></name><name name-style="western"><surname>Hanna</surname><given-names>GJ</given-names></name><name name-style="western"><surname>Laga</surname><given-names>AC</given-names></name><name name-style="western"><surname>Haddad</surname><given-names>RI</given-names></name><name name-style="western"><surname>Lorch</surname><given-names>JH</given-names></name><name name-style="western"><surname>Hammerman</surname><given-names>PS</given-names></name></person-group>. <article-title>Genomic analysis of metastatic cutaneous squamous cell carcinoma</article-title>. <source>Clin Cancer Res</source> (<year>2015</year>) <volume>21</volume>(<issue>6</issue>):<page-range>1447–56</page-range>. doi: <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-14-1773</pub-id><pub-id pub-id-type="pmcid">PMC4359951</pub-id><pub-id pub-id-type="pmid">25589618</pub-id></mixed-citation>
        </ref>
        <ref id="B20">
          <label>20</label>
          <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chang</surname><given-names>D</given-names></name><name name-style="western"><surname>Shain</surname><given-names>AH</given-names></name></person-group>. <article-title>The landscape of driver mutations in cutaneous squamous cell carcinoma</article-title>. <source>NPJ Genom Med</source> (<year>2021</year>) <volume>6</volume>(<issue>1</issue>):<fpage>61</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41525-021-00226-4</pub-id><pub-id pub-id-type="pmid">34272401</pub-id><pub-id pub-id-type="pmcid">PMC8285521</pub-id></mixed-citation>
        </ref>
        <ref id="B21">
          <label>21</label>
          <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pickering</surname><given-names>CR</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>JH</given-names></name><name name-style="western"><surname>Lee</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Drummond</surname><given-names>JA</given-names></name><name name-style="western"><surname>Peng</surname><given-names>SA</given-names></name><name name-style="western"><surname>Saade</surname><given-names>RE</given-names></name><etal/></person-group>. <article-title>Mutational landscape of aggressive cutaneous squamous cell carcinoma</article-title>. <source>Clin Cancer Res</source> (<year>2014</year>) <volume>20</volume>(<issue>24</issue>):<page-range>6582–92</page-range>. doi: <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-14-1768</pub-id><pub-id pub-id-type="pmcid">PMC4367811</pub-id><pub-id pub-id-type="pmid">25303977</pub-id></mixed-citation>
        </ref>
        <ref id="B22">
          <label>22</label>
          <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lawrence</surname><given-names>MS</given-names></name><name name-style="western"><surname>Stojanov</surname><given-names>P</given-names></name><name name-style="western"><surname>Polak</surname><given-names>P</given-names></name><name name-style="western"><surname>Kryukov</surname><given-names>GV</given-names></name><name name-style="western"><surname>Cibulskis</surname><given-names>K</given-names></name><name name-style="western"><surname>Sivachenko</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Mutational heterogeneity in cancer and the search for new cancer-associated genes</article-title>. <source>Nature</source> (<year>2013</year>) <volume>499</volume>(<issue>7457</issue>):<page-range>214–8</page-range>. doi: <pub-id pub-id-type="doi">10.1038/nature12213</pub-id><pub-id pub-id-type="pmcid">PMC3919509</pub-id><pub-id pub-id-type="pmid">23770567</pub-id></mixed-citation>
        </ref>
        <ref id="B23">
          <label>23</label>
          <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hedegaard</surname><given-names>J</given-names></name><name name-style="western"><surname>Thorsen</surname><given-names>K</given-names></name><name name-style="western"><surname>Lund</surname><given-names>MK</given-names></name><name name-style="western"><surname>Hein</surname><given-names>AM</given-names></name><name name-style="western"><surname>Hamilton-Dutoit</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Vang</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Next-generation sequencing of RNA and DNA isolated from paired fresh-frozen and formalin-fixed paraffin-embedded samples of human cancer and normal tissue</article-title>. <source>PloS One</source> (<year>2014</year>) <volume>9</volume>(<issue>5</issue>):<elocation-id>e98187</elocation-id>. doi: <pub-id pub-id-type="doi">10.1371/journal.pone.0098187</pub-id><pub-id pub-id-type="pmid">24878701</pub-id><pub-id pub-id-type="pmcid">PMC4039489</pub-id></mixed-citation>
        </ref>
        <ref id="B24">
          <label>24</label>
          <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Statello</surname><given-names>L</given-names></name><name name-style="western"><surname>Guo</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Chen</surname><given-names>LL</given-names></name><name name-style="western"><surname>Huarte</surname><given-names>M</given-names></name></person-group>. <article-title>Author correction: Gene regulation by long non-coding RNAs and its biological functions</article-title>. <source>Nat Rev Mol Cell Biol</source> (<year>2021</year>) <volume>22</volume>(<issue>2</issue>):<fpage>159</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41580-021-00330-4</pub-id><pub-id pub-id-type="pmcid">PMC8095262</pub-id><pub-id pub-id-type="pmid">33420484</pub-id></mixed-citation>
        </ref>
        <ref id="B25">
          <label>25</label>
          <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cesana</surname><given-names>M</given-names></name><name name-style="western"><surname>Cacchiarelli</surname><given-names>D</given-names></name><name name-style="western"><surname>Legnini</surname><given-names>I</given-names></name><name name-style="western"><surname>Santini</surname><given-names>T</given-names></name><name name-style="western"><surname>Sthandier</surname><given-names>O</given-names></name><name name-style="western"><surname>Chinappi</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>A long noncoding RNA controls muscle differentiation by functioning as a competing endogenous RNA</article-title>. <source>Cell</source> (<year>2011</year>) <volume>147</volume>(<issue>2</issue>):<page-range>358–69</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.cell.2011.09.028</pub-id><pub-id pub-id-type="pmcid">PMC3234495</pub-id><pub-id pub-id-type="pmid">22000014</pub-id></mixed-citation>
        </ref>
        <ref id="B26">
          <label>26</label>
          <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barrett</surname><given-names>LW</given-names></name><name name-style="western"><surname>Fletcher</surname><given-names>S</given-names></name><name name-style="western"><surname>Wilton</surname><given-names>SD</given-names></name></person-group>. <article-title>Regulation of eukaryotic gene expression by the untranslated gene regions and other non-coding elements</article-title>. <source>Cell Mol Life Sci</source> (<year>2012</year>) <volume>69</volume>(<issue>21</issue>):<page-range>3613–34</page-range>. doi: <pub-id pub-id-type="doi">10.1007/s00018-012-0990-9</pub-id><pub-id pub-id-type="pmcid">PMC3474909</pub-id><pub-id pub-id-type="pmid">22538991</pub-id></mixed-citation>
        </ref>
        <ref id="B27">
          <label>27</label>
          <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>W</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name></person-group>. <article-title>Prediction of functional microRNA targets by integrative modeling of microRNA binding and target expression data</article-title>. <source>Genome Biol</source> (<year>2019</year>) <volume>20</volume>(<issue>1</issue>):<fpage>18</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s13059-019-1629-z</pub-id><pub-id pub-id-type="pmid">30670076</pub-id><pub-id pub-id-type="pmcid">PMC6341724</pub-id></mixed-citation>
        </ref>
        <ref id="B28">
          <label>28</label>
          <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schuster</surname><given-names>SL</given-names></name><name name-style="western"><surname>Hsieh</surname><given-names>AC</given-names></name></person-group>. <article-title>The untranslated regions of mRNAs in cancer</article-title>. <source>Trends Cancer</source> (<year>2019</year>) <volume>5</volume>(<issue>4</issue>):<page-range>245–62</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.trecan.2019.02.011</pub-id><pub-id pub-id-type="pmcid">PMC6465068</pub-id><pub-id pub-id-type="pmid">30961831</pub-id></mixed-citation>
        </ref>
        <ref id="B29">
          <label>29</label>
          <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kobayashi</surname><given-names>H</given-names></name><name name-style="western"><surname>Tomari</surname><given-names>Y</given-names></name></person-group>. <article-title>RISC assembly: Coordination between small RNAs and argonaute proteins</article-title>. <source>Biochim Biophys Acta (BBA)-Gene Regul Mech</source> (<year>2016</year>) <volume>1859</volume>(<issue>1</issue>):<fpage>71</fpage>–<lpage>81</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.bbagrm.2015.08.007</pub-id><pub-id pub-id-type="pmid">26303205</pub-id></mixed-citation>
        </ref>
        <ref id="B30">
          <label>30</label>
          <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Priestley</surname><given-names>P</given-names></name><name name-style="western"><surname>Baber</surname><given-names>J</given-names></name><name name-style="western"><surname>Lolkema</surname><given-names>MP</given-names></name><name name-style="western"><surname>Steeghs</surname><given-names>N</given-names></name><name name-style="western"><surname>de Bruijn</surname><given-names>E</given-names></name><name name-style="western"><surname>Shale</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Pan-cancer whole-genome analyses of metastatic solid tumours</article-title>. <source>Nature</source> (<year>2019</year>) <volume>575</volume>(<issue>7781</issue>):<page-range>210–6</page-range>. doi: <pub-id pub-id-type="doi">10.1038/s41586-019-1689-y</pub-id><pub-id pub-id-type="pmcid">PMC6872491</pub-id><pub-id pub-id-type="pmid">31645765</pub-id></mixed-citation>
        </ref>
        <ref id="B31">
          <label>31</label>
          <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pagel</surname><given-names>KA</given-names></name><name name-style="western"><surname>Kim</surname><given-names>R</given-names></name><name name-style="western"><surname>Moad</surname><given-names>K</given-names></name><name name-style="western"><surname>Busby</surname><given-names>B</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>L</given-names></name><name name-style="western"><surname>Tokheim</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Integrated informatics analysis of cancer-related variants</article-title>. <source>JCO Clin Cancer Inform</source> (<year>2020</year>) <volume>4</volume>:<page-range>310–7</page-range>. doi: <pub-id pub-id-type="doi">10.1200/CCI.19.00132</pub-id><pub-id pub-id-type="pmcid">PMC7113103</pub-id><pub-id pub-id-type="pmid">32228266</pub-id></mixed-citation>
        </ref>
        <ref id="B32">
          <label>32</label>
          <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mularoni</surname><given-names>L</given-names></name><name name-style="western"><surname>Sabarinathan</surname><given-names>R</given-names></name><name name-style="western"><surname>Deu-Pons</surname><given-names>J</given-names></name><name name-style="western"><surname>Gonzalez-Perez</surname><given-names>A</given-names></name><name name-style="western"><surname>López-Bigas</surname><given-names>N</given-names></name></person-group>. <article-title>OncodriveFML: A general framework to identify coding and non-coding regions with cancer driver mutations</article-title>. <source>Genome Biol</source> (<year>2016</year>) <volume>17</volume>(<issue>1</issue>):<fpage>128</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s13059-016-0994-0</pub-id><pub-id pub-id-type="pmid">27311963</pub-id><pub-id pub-id-type="pmcid">PMC4910259</pub-id></mixed-citation>
        </ref>
        <ref id="B33">
          <label>33</label>
          <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Martincorena</surname><given-names>I</given-names></name><name name-style="western"><surname>Raine</surname><given-names>KM</given-names></name><name name-style="western"><surname>Gerstung</surname><given-names>M</given-names></name><name name-style="western"><surname>Dawson</surname><given-names>KJ</given-names></name><name name-style="western"><surname>Haase</surname><given-names>K</given-names></name><name name-style="western"><surname>Van Loo</surname><given-names>P</given-names></name><etal/></person-group>. <article-title>Universal patterns of selection in cancer and somatic tissues</article-title>. <source>Cell</source> (<year>2017</year>) <volume>171</volume>(<issue>5</issue>):<fpage>1029</fpage>–<lpage>1041.e21</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.cell.2017.09.042</pub-id><pub-id pub-id-type="pmid">29056346</pub-id><pub-id pub-id-type="pmcid">PMC5720395</pub-id></mixed-citation>
        </ref>
        <ref id="B34">
          <label>34</label>
          <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gao</surname><given-names>J</given-names></name><name name-style="western"><surname>Aksoy</surname><given-names>BA</given-names></name><name name-style="western"><surname>Dogrusoz</surname><given-names>U</given-names></name><name name-style="western"><surname>Dresdner</surname><given-names>G</given-names></name><name name-style="western"><surname>Gross</surname><given-names>B</given-names></name><name name-style="western"><surname>Sumer</surname><given-names>SO</given-names></name><etal/></person-group>. <article-title>Integrative analysis of complex cancer genomics and clinical profiles using the cbioportal</article-title>. <source>Sci Signal</source> (<year>2013</year>) <volume>6</volume>(<issue>269</issue>):<fpage>pl1</fpage>. doi: <pub-id pub-id-type="doi">10.1126/scisignal.2004088</pub-id><pub-id pub-id-type="pmid">23550210</pub-id><pub-id pub-id-type="pmcid">PMC4160307</pub-id></mixed-citation>
        </ref>
        <ref id="B35">
          <label>35</label>
          <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cerami</surname><given-names>E</given-names></name><name name-style="western"><surname>Gao</surname><given-names>J</given-names></name><name name-style="western"><surname>Dogrusoz</surname><given-names>U</given-names></name><name name-style="western"><surname>Gross</surname><given-names>BE</given-names></name><name name-style="western"><surname>Sumer</surname><given-names>SO</given-names></name><name name-style="western"><surname>Aksoy</surname><given-names>BA</given-names></name><etal/></person-group>. <article-title>The cbio cancer genomics portal: An open platform for exploring multidimensional cancer genomics data</article-title>. <source>Cancer Discovery</source> (<year>2012</year>) <volume>2</volume>(<issue>5</issue>):<page-range>401–4</page-range>. doi: <pub-id pub-id-type="doi">10.1158/2159-8290.CD-12-0095</pub-id><pub-id pub-id-type="pmcid">PMC3956037</pub-id><pub-id pub-id-type="pmid">22588877</pub-id></mixed-citation>
        </ref>
        <ref id="B36">
          <label>36</label>
          <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cameron</surname><given-names>DL</given-names></name><name name-style="western"><surname>Baber</surname><given-names>J</given-names></name><name name-style="western"><surname>Shale</surname><given-names>C</given-names></name><name name-style="western"><surname>Valle-Inclan</surname><given-names>JE</given-names></name><name name-style="western"><surname>Besselink</surname><given-names>N</given-names></name><name name-style="western"><surname>van Hoeck</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>GRIDSS2: Comprehensive characterisation of somatic structural variation using single breakend variants and structural variant phasing</article-title>. <source>Genome Biol</source> (<year>2021</year>) <volume>22</volume>(<issue>1</issue>):<fpage>202</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s13059-021-02423-x</pub-id><pub-id pub-id-type="pmid">34253237</pub-id><pub-id pub-id-type="pmcid">PMC8274009</pub-id></mixed-citation>
        </ref>
        <ref id="B37">
          <label>37</label>
          <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Blokzijl</surname><given-names>F</given-names></name><etal/></person-group>. <article-title>MutationalPatterns: Comprehensive genome-wide analysis of mutational processes</article-title>. <source>Genome Med</source> (<year>2018</year>) <volume>10</volume>(<issue>1</issue>):<fpage>1</fpage>–<lpage>11</lpage>. doi: <pub-id pub-id-type="doi">10.1186/s13073-018-0539-0</pub-id><pub-id pub-id-type="pmid">29695279</pub-id><pub-id pub-id-type="pmcid">PMC5922316</pub-id></mixed-citation>
        </ref>
        <ref id="B38">
          <label>38</label>
          <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kuleshov</surname><given-names>MV</given-names></name><name name-style="western"><surname>Jones</surname><given-names>MR</given-names></name><name name-style="western"><surname>Rouillard</surname><given-names>AD</given-names></name><name name-style="western"><surname>Fernandez</surname><given-names>NF</given-names></name><name name-style="western"><surname>Duan</surname><given-names>Q</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z</given-names></name><etal/></person-group>. <article-title>Enrichr: A comprehensive gene set enrichment analysis web server 2016 update</article-title>. <source>Nucleic Acids Res</source> (<year>2016</year>) <volume>44</volume>(<issue>W1</issue>):<page-range>W90–7</page-range>. doi: <pub-id pub-id-type="doi">10.1093/nar/gkw377</pub-id><pub-id pub-id-type="pmcid">PMC4987924</pub-id><pub-id pub-id-type="pmid">27141961</pub-id></mixed-citation>
        </ref>
        <ref id="B39">
          <label>39</label>
          <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wilson A</surname><given-names>GD</given-names></name><name name-style="western"><surname>Nankervis</surname><given-names>J</given-names></name><name name-style="western"><surname>Clark</surname><given-names>J</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>R</given-names></name><name name-style="western"><surname>Ashford</surname><given-names>B</given-names></name></person-group>. <article-title>Defining the incidence of cutaneous squamous cell carcinoma in coastal NSW Australia</article-title>. <source>Aust J Derm</source> (<year>2022</year>) <volume>63</volume>(<issue>2</issue>):<page-range>213–6</page-range>. doi: <pub-id pub-id-type="doi">10.1111/ajd.13830</pub-id><pub-id pub-id-type="pmcid">PMC9321870</pub-id><pub-id pub-id-type="pmid">35397123</pub-id></mixed-citation>
        </ref>
        <ref id="B40">
          <label>40</label>
          <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tokez</surname><given-names>S</given-names></name><name name-style="western"><surname>Wakkee</surname><given-names>M</given-names></name><name name-style="western"><surname>Kan</surname><given-names>W</given-names></name><name name-style="western"><surname>Venables</surname><given-names>ZC</given-names></name><name name-style="western"><surname>Mooyaart</surname><given-names>AL</given-names></name><name name-style="western"><surname>Louwman</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Cumulative incidence and disease-specific survival of metastatic cutaneous squamous cell carcinoma: A nationwide cancer registry study</article-title>. <source>J Am Acad Dermatol</source> (<year>2021</year>) <volume>86</volume>(<issue>2</issue>):<page-range>331–8</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.jaad.2021.09.067</pub-id><pub-id pub-id-type="pmid">34653569</pub-id></mixed-citation>
        </ref>
        <ref id="B41">
          <label>41</label>
          <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mao</surname><given-names>P</given-names></name><name name-style="western"><surname>Brown</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Esaki</surname><given-names>S</given-names></name><name name-style="western"><surname>Lockwood</surname><given-names>S</given-names></name><name name-style="western"><surname>Poon</surname><given-names>GMK</given-names></name><name name-style="western"><surname>Smerdon</surname><given-names>MJ</given-names></name><etal/></person-group>. <article-title>ETS transcription factors induce a unique UV damage signature that drives recurrent mutagenesis in melanoma</article-title>. <source>Nat Commun</source> (<year>2018</year>) <volume>9</volume>(<issue>1</issue>):<fpage>2626</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41467-018-05064-0</pub-id><pub-id pub-id-type="pmid">29980679</pub-id><pub-id pub-id-type="pmcid">PMC6035183</pub-id></mixed-citation>
        </ref>
        <ref id="B42">
          <label>42</label>
          <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Perera</surname><given-names>D</given-names></name><name name-style="western"><surname>Poulos</surname><given-names>RC</given-names></name><name name-style="western"><surname>Shah</surname><given-names>A</given-names></name><name name-style="western"><surname>Beck</surname><given-names>D</given-names></name><name name-style="western"><surname>Pimanda</surname><given-names>JE</given-names></name><name name-style="western"><surname>Wong</surname><given-names>JW</given-names></name></person-group>. <article-title>Differential DNA repair underlies mutation hotspots at active promoters in cancer genomes</article-title>. <source>Nature</source> (<year>2016</year>) <volume>532</volume>(<issue>7598</issue>):<page-range>259–63</page-range>. doi: <pub-id pub-id-type="doi">10.1038/nature17437</pub-id><pub-id pub-id-type="pmid">27075100</pub-id></mixed-citation>
        </ref>
        <ref id="B43">
          <label>43</label>
          <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sabarinathan</surname><given-names>R</given-names></name><name name-style="western"><surname>Mularoni</surname><given-names>L</given-names></name><name name-style="western"><surname>Deu-Pons</surname><given-names>J</given-names></name><name name-style="western"><surname>Gonzalez-Perez</surname><given-names>A</given-names></name><name name-style="western"><surname>López-Bigas</surname><given-names>N</given-names></name></person-group>. <article-title>Nucleotide excision repair is impaired by binding of transcription factors to DNA</article-title>. <source>Nature</source> (<year>2016</year>) <volume>532</volume>(<issue>7598</issue>):<page-range>264–7</page-range>. doi: <pub-id pub-id-type="doi">10.1038/nature17661</pub-id><pub-id pub-id-type="pmid">27075101</pub-id></mixed-citation>
        </ref>
        <ref id="B44">
          <label>44</label>
          <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Purdie</surname><given-names>KJ</given-names></name><name name-style="western"><surname>Harwood</surname><given-names>CA</given-names></name><name name-style="western"><surname>Gulati</surname><given-names>A</given-names></name><name name-style="western"><surname>Chaplin</surname><given-names>T</given-names></name><name name-style="western"><surname>Lambert</surname><given-names>SR</given-names></name><name name-style="western"><surname>Cerio</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Single nucleotide polymorphism array analysis defines a specific genetic fingerprint for well-differentiated cutaneous SCCs</article-title>. <source>J Invest Dermatol</source> (<year>2009</year>) <volume>129</volume>(<issue>6</issue>):<page-range>1562–8</page-range>. doi: <pub-id pub-id-type="doi">10.1038/jid.2008.408</pub-id><pub-id pub-id-type="pmcid">PMC3042680</pub-id><pub-id pub-id-type="pmid">19131950</pub-id></mixed-citation>
        </ref>
        <ref id="B45">
          <label>45</label>
          <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lambert</surname><given-names>SR</given-names></name><name name-style="western"><surname>Harwood</surname><given-names>CA</given-names></name><name name-style="western"><surname>Purdie</surname><given-names>KJ</given-names></name><name name-style="western"><surname>Gulati</surname><given-names>A</given-names></name><name name-style="western"><surname>Matin</surname><given-names>RN</given-names></name><name name-style="western"><surname>Romanowska</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Metastatic cutaneous squamous cell carcinoma shows frequent deletion in the protein tyrosine phosphatase receptor type d gene</article-title>. <source>Int J Cancer</source> (<year>2012</year>) <volume>131</volume>(<issue>3</issue>):<page-range>E216–26</page-range>. doi: <pub-id pub-id-type="doi">10.1002/ijc.27333</pub-id><pub-id pub-id-type="pmid">22052591</pub-id></mixed-citation>
        </ref>
        <ref id="B46">
          <label>46</label>
          <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Du</surname><given-names>QY</given-names></name><name name-style="western"><surname>Yao</surname><given-names>JH</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>YC</given-names></name><name name-style="western"><surname>Xu</surname><given-names>LJ</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>FY</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y</given-names></name></person-group>. <article-title>High STRN expression promotes HCC invasion and migration but not cell proliferation or apoptosis through facilitating epithelial-mesenchymal transition</article-title>. <source>BioMed Res Int 2020</source> (<year>2020</year>), <fpage>6152925</fpage>. doi: <pub-id pub-id-type="doi">10.1155/2020/6152925</pub-id><pub-id pub-id-type="pmcid">PMC7125443</pub-id><pub-id pub-id-type="pmid">32280692</pub-id></mixed-citation>
        </ref>
        <ref id="B47">
          <label>47</label>
          <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shao</surname><given-names>YW</given-names></name><name name-style="western"><surname>Wood</surname><given-names>GA</given-names></name><name name-style="western"><surname>Lu</surname><given-names>J</given-names></name><name name-style="western"><surname>Tang</surname><given-names>QL</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J</given-names></name><name name-style="western"><surname>Molyneux</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Cross-species genomics identifies DLG2 as a tumor suppressor in osteosarcoma</article-title>. <source>Oncogene</source> (<year>2019</year>) <volume>38</volume>(<issue>2</issue>):<page-range>291–8</page-range>. doi: <pub-id pub-id-type="doi">10.1038/s41388-018-0444-4</pub-id><pub-id pub-id-type="pmcid">PMC6756098</pub-id><pub-id pub-id-type="pmid">30093633</pub-id></mixed-citation>
        </ref>
        <ref id="B48">
          <label>48</label>
          <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>R</given-names></name><name name-style="western"><surname>Grishagin</surname><given-names>I</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>T</given-names></name><name name-style="western"><surname>Greene</surname><given-names>J</given-names></name><name name-style="western"><surname>Obenauer</surname><given-names>JC</given-names></name><etal/></person-group>. <article-title>The NCATS BioPlanet – an integrated platform for exploring the universe of cellular signaling pathways for toxicology, systems biology, and chemical genomics</article-title>. <source>Front Pharmacol</source> (<year>2019</year>) <volume>10</volume>. doi: <pub-id pub-id-type="doi">10.3389/fphar.2019.00445</pub-id><pub-id pub-id-type="pmcid">PMC6524730</pub-id><pub-id pub-id-type="pmid">31133849</pub-id></mixed-citation>
        </ref>
        <ref id="B49">
          <label>49</label>
          <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yoo</surname><given-names>M</given-names></name><name name-style="western"><surname>Shin</surname><given-names>J</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J</given-names></name><name name-style="western"><surname>Ryall</surname><given-names>KA</given-names></name><name name-style="western"><surname>Lee</surname><given-names>K</given-names></name><name name-style="western"><surname>Lee</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>DSigDB: Drug signatures database for gene set analysis</article-title>. <source>Bioinformatics</source> (<year>2015</year>) <volume>31</volume>(<issue>18</issue>):<page-range>3069–71</page-range>. doi: <pub-id pub-id-type="doi">10.1093/bioinformatics/btv313</pub-id><pub-id pub-id-type="pmcid">PMC4668778</pub-id><pub-id pub-id-type="pmid">25990557</pub-id></mixed-citation>
        </ref>
        <ref id="B50">
          <label>50</label>
          <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Agarwal</surname><given-names>V</given-names></name><name name-style="western"><surname>Bell</surname><given-names>GW</given-names></name><name name-style="western"><surname>Nam</surname><given-names>JW</given-names></name><name name-style="western"><surname>Bartel</surname><given-names>DP</given-names></name></person-group>. <article-title>Predicting effective microRNA target sites in mammalian mRNAs</article-title>. <source>Elife</source> (<year>2015</year>) <volume>4</volume>:<elocation-id>e05005</elocation-id>. doi: <pub-id pub-id-type="doi">10.7554/eLife.05005</pub-id><pub-id pub-id-type="pmcid">PMC4532895</pub-id><pub-id pub-id-type="pmid">26267216</pub-id></mixed-citation>
        </ref>
        <ref id="B51">
          <label>51</label>
          <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hayward</surname><given-names>NK</given-names></name><name name-style="western"><surname>Wilmott</surname><given-names>JS</given-names></name><name name-style="western"><surname>Waddell</surname><given-names>N</given-names></name><name name-style="western"><surname>Johansson</surname><given-names>PA</given-names></name><name name-style="western"><surname>Field</surname><given-names>MA</given-names></name><name name-style="western"><surname>Nones</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>Whole-genome landscapes of major melanoma subtypes</article-title>. <source>Nature</source> (<year>2017</year>) <volume>545</volume>(<issue>7653</issue>):<page-range>175–80</page-range>. doi: <pub-id pub-id-type="doi">10.1038/nature22071</pub-id><pub-id pub-id-type="pmid">28467829</pub-id></mixed-citation>
        </ref>
        <ref id="B52">
          <label>52</label>
          <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alexandrov</surname><given-names>LB</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J</given-names></name><name name-style="western"><surname>Haradhvala</surname><given-names>NJ</given-names></name><name name-style="western"><surname>Huang</surname><given-names>MN</given-names></name><name name-style="western"><surname>Tian Ng</surname><given-names>AW</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>The repertoire of mutational signatures in human cancer</article-title>. <source>Nature</source> (<year>2020</year>) <volume>578</volume>(<issue>7793</issue>):<fpage>94</fpage>–<lpage>101</lpage>. doi: <pub-id pub-id-type="doi">10.1038/s41586-020-1943-3</pub-id><pub-id pub-id-type="pmid">32025018</pub-id><pub-id pub-id-type="pmcid">PMC7054213</pub-id></mixed-citation>
        </ref>
        <ref id="B53">
          <label>53</label>
          <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tate</surname><given-names>JG</given-names></name><name name-style="western"><surname>Bamford</surname><given-names>S</given-names></name><name name-style="western"><surname>Jubb</surname><given-names>HC</given-names></name><name name-style="western"><surname>Sondka</surname><given-names>Z</given-names></name><name name-style="western"><surname>Beare</surname><given-names>DM</given-names></name><name name-style="western"><surname>Bindal</surname><given-names>N</given-names></name><etal/></person-group>. <article-title>COSMIC: The catalogue of somatic mutations in cancer</article-title>. <source>Nucleic Acids Res</source> (<year>2019</year>) <volume>47</volume>(<issue>D1</issue>):<fpage>D941</fpage>–<lpage>d947</lpage>. doi: <pub-id pub-id-type="doi">10.1093/nar/gky1015</pub-id><pub-id pub-id-type="pmid">30371878</pub-id><pub-id pub-id-type="pmcid">PMC6323903</pub-id></mixed-citation>
        </ref>
        <ref id="B54">
          <label>54</label>
          <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Takahashi</surname><given-names>R</given-names></name><name name-style="western"><surname>Yamagishi</surname><given-names>M</given-names></name><name name-style="western"><surname>Nakano</surname><given-names>K</given-names></name><name name-style="western"><surname>Yamochi</surname><given-names>T</given-names></name><name name-style="western"><surname>Yamochi</surname><given-names>T</given-names></name><name name-style="western"><surname>Fujikawa</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Epigenetic deregulation of Ellis van creveld confers robust hedgehog signaling in adult T-cell leukemia</article-title>. <source>Cancer Sci</source> (<year>2014</year>) <volume>105</volume>(<issue>9</issue>):<page-range>1160–9</page-range>. doi: <pub-id pub-id-type="doi">10.1111/cas.12480</pub-id><pub-id pub-id-type="pmcid">PMC4462393</pub-id><pub-id pub-id-type="pmid">24996003</pub-id></mixed-citation>
        </ref>
        <ref id="B55">
          <label>55</label>
          <mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Mamoor</surname><given-names>S</given-names></name></person-group>. <source>EVC is differentially expressed in lymph node metastasis in human breast cancer</source>. <publisher-name>OSF Preprints</publisher-name> (<year>2021</year>). doi: <pub-id pub-id-type="doi">10.31219/osf.io/twb9n</pub-id></mixed-citation>
        </ref>
        <ref id="B56">
          <label>56</label>
          <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chakravarti</surname><given-names>S</given-names></name></person-group>. <article-title>Functions of lumican and fibromodulin: Lessons from knockout mice</article-title>. <source>Glycoconjugate J</source> (<year>2002</year>) <volume>19</volume>(<issue>4</issue>):<page-range>287–93</page-range>. doi: <pub-id pub-id-type="doi">10.1023/A:1025348417078</pub-id><pub-id pub-id-type="pmid">12975607</pub-id></mixed-citation>
        </ref>
        <ref id="B57">
          <label>57</label>
          <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Luo</surname><given-names>W</given-names></name><name name-style="western"><surname>Xu</surname><given-names>C</given-names></name><name name-style="western"><surname>Ayello</surname><given-names>J</given-names></name><name name-style="western"><surname>Dela Cruz</surname><given-names>F</given-names></name><name name-style="western"><surname>Rosenblum</surname><given-names>JM</given-names></name><name name-style="western"><surname>Lessnick</surname><given-names>SL</given-names></name><etal/></person-group>. <article-title>Protein phosphatase 1 regulatory subunit 1A in Ewing sarcoma tumorigenesis and metastasis</article-title>. <source>Oncogene</source> (<year>2018</year>) <volume>37</volume>(<issue>6</issue>):<fpage>798</fpage>–<lpage>809</lpage>. doi: <pub-id pub-id-type="doi">10.1038/onc.2017.378</pub-id><pub-id pub-id-type="pmid">29059150</pub-id></mixed-citation>
        </ref>
        <ref id="B58">
          <label>58</label>
          <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yuan</surname><given-names>CL</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>XM</given-names></name><name name-style="western"><surname>Yi</surname><given-names>Y</given-names></name><name name-style="western"><surname>E</surname><given-names>JF</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>ND</given-names></name><name name-style="western"><surname>Luo</surname><given-names>X</given-names></name><etal/></person-group>. <article-title>Identification of differentially expressed lncRNAs and mRNAs in luminal-b breast cancer by RNA-sequencing</article-title>. <source>BMC Cancer</source> (<year>2019</year>) <volume>19</volume>(<issue>1</issue>):<fpage>1171</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s12885-019-6395-5</pub-id><pub-id pub-id-type="pmid">31795964</pub-id><pub-id pub-id-type="pmcid">PMC6889534</pub-id></mixed-citation>
        </ref>
        <ref id="B59">
          <label>59</label>
          <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>L</given-names></name><name name-style="western"><surname>Xia</surname><given-names>L</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X</given-names></name><name name-style="western"><surname>Ruan</surname><given-names>M</given-names></name><name name-style="western"><surname>Li</surname><given-names>L</given-names></name><name name-style="western"><surname>Xia</surname><given-names>R</given-names></name></person-group>. <article-title>Long non-coding RNA LINC01003 suppresses the development of multiple myeloma by targeting miR-33a-5p/PIM1 axis</article-title>. <source>Leuk Res</source> (<year>2021</year>) <volume>106</volume>:<fpage>106565</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.leukres.2021.106565</pub-id><pub-id pub-id-type="pmid">33865032</pub-id></mixed-citation>
        </ref>
        <ref id="B60">
          <label>60</label>
          <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Assoun</surname><given-names>S</given-names></name><name name-style="western"><surname>Theou-Anton</surname><given-names>N</given-names></name><name name-style="western"><surname>Nguenang</surname><given-names>M</given-names></name><name name-style="western"><surname>Cazes</surname><given-names>A</given-names></name><name name-style="western"><surname>Danel</surname><given-names>C</given-names></name><name name-style="western"><surname>Abbar</surname><given-names>B</given-names></name><etal/></person-group>. <article-title>Association of TP53 mutations with response and longer survival under immune checkpoint inhibitors in advanced non-Small-Cell lung cancer</article-title>. <source>Lung Cancer</source> (<year>2019</year>) <volume>132</volume>:<fpage>65</fpage>–<lpage>71</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.lungcan.2019.04.005</pub-id><pub-id pub-id-type="pmid">31097096</pub-id></mixed-citation>
        </ref>
        <ref id="B61">
          <label>61</label>
          <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Deneka</surname><given-names>AY</given-names></name><name name-style="western"><surname>Baca</surname><given-names>Y</given-names></name><name name-style="western"><surname>Serebriiskii</surname><given-names>IG</given-names></name><name name-style="western"><surname>Nicolas</surname><given-names>E</given-names></name><name name-style="western"><surname>Parker</surname><given-names>MI</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>TT</given-names></name><etal/></person-group>. <article-title>Association of T P53 and CDKN2A mutation profile with tumor mutation burden in head and neck cancer</article-title>. <source>Clin Cancer Res</source> (<year>2022</year>) <volume>28</volume>(<issue>9</issue>):<page-range>1925–37</page-range>. doi: <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-21-4316</pub-id><pub-id pub-id-type="pmcid">PMC9186806</pub-id><pub-id pub-id-type="pmid">35491653</pub-id></mixed-citation>
        </ref>
        <ref id="B62">
          <label>62</label>
          <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Klinakis</surname><given-names>A</given-names></name><name name-style="western"><surname>Rampias</surname><given-names>T</given-names></name></person-group>. <article-title>TP53 mutational landscape of metastatic head and neck cancer reveals patterns of mutation selection</article-title>. <source>EBioMedicine</source> (<year>2020</year>) <volume>58</volume>:<fpage>102905</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.ebiom.2020.102905</pub-id><pub-id pub-id-type="pmid">32739866</pub-id><pub-id pub-id-type="pmcid">PMC7393519</pub-id></mixed-citation>
        </ref>
        <ref id="B63">
          <label>63</label>
          <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>R</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Q</given-names></name><name name-style="western"><surname>Li</surname><given-names>T</given-names></name><name name-style="western"><surname>Liao</surname><given-names>Q</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Y</given-names></name></person-group>. <article-title>Role of the complement system in the tumor microenvironment</article-title>. <source>Cancer Cell Int</source> (<year>2019</year>) <volume>19</volume>:<fpage>300</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s12935-019-1027-3</pub-id><pub-id pub-id-type="pmid">31787848</pub-id><pub-id pub-id-type="pmcid">PMC6858723</pub-id></mixed-citation>
        </ref>
        <ref id="B64">
          <label>64</label>
          <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rahmati Nezhad</surname><given-names>P</given-names></name><name name-style="western"><surname>Riihila</surname><given-names>P</given-names></name><name name-style="western"><surname>Knuutila</surname><given-names>JS</given-names></name><name name-style="western"><surname>Viiklepp</surname><given-names>K</given-names></name><name name-style="western"><surname>Peltonen</surname><given-names>S</given-names></name><name name-style="western"><surname>Kallajoki</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Complement factor d is a novel biomarker and putative therapeutic target in cutaneous squamous cell carcinoma</article-title>. <source>Cancers (Basel)</source> (<year>2022</year>) <volume>14</volume>(<issue>2</issue>):<fpage>305</fpage>. doi: <pub-id pub-id-type="doi">10.3390/cancers14020305</pub-id><pub-id pub-id-type="pmid">35053469</pub-id><pub-id pub-id-type="pmcid">PMC8773783</pub-id></mixed-citation>
        </ref>
        <ref id="B65">
          <label>65</label>
          <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Johnson</surname><given-names>EM</given-names></name><name name-style="western"><surname>Uppalapati</surname><given-names>CK</given-names></name><name name-style="western"><surname>Pascual</surname><given-names>AS</given-names></name><name name-style="western"><surname>Estrada</surname><given-names>SI</given-names></name><name name-style="western"><surname>Averitte</surname><given-names>RL</given-names></name><name name-style="western"><surname>Leyva</surname><given-names>KJ</given-names></name><etal/></person-group>. <article-title>Complement factor h in cSCC: Evidence of a link between sun exposure and immunosuppression in skin cancer progression</article-title>. <source>Front Oncol</source> (<year>2022</year>) <volume>12</volume>:<elocation-id>819580</elocation-id>. doi: <pub-id pub-id-type="doi">10.3389/fonc.2022.819580</pub-id><pub-id pub-id-type="pmid">35223500</pub-id><pub-id pub-id-type="pmcid">PMC8869607</pub-id></mixed-citation>
        </ref>
        <ref id="B66">
          <label>66</label>
          <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Riihila</surname><given-names>P</given-names></name><name name-style="western"><surname>Nissinen</surname><given-names>L</given-names></name><name name-style="western"><surname>Knuutila</surname><given-names>J</given-names></name><name name-style="western"><surname>Rahmati Nezhad</surname><given-names>P</given-names></name><name name-style="western"><surname>Viiklepp</surname><given-names>K</given-names></name><name name-style="western"><surname>Kahari</surname><given-names>VM</given-names></name><etal/></person-group>. <article-title>Complement system in cutaneous squamous cell carcinoma</article-title>. <source>Int J Mol Sci</source> (<year>2019</year>) <volume>20</volume>(<issue>14</issue>):<fpage>3550</fpage>. doi: <pub-id pub-id-type="doi">10.3390/ijms20143550</pub-id><pub-id pub-id-type="pmcid">PMC6678994</pub-id><pub-id pub-id-type="pmid">31331124</pub-id></mixed-citation>
        </ref>
        <ref id="B67">
          <label>67</label>
          <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chong</surname><given-names>PK</given-names></name><name name-style="western"><surname>Lee</surname><given-names>H</given-names></name><name name-style="western"><surname>Loh</surname><given-names>MC</given-names></name><name name-style="western"><surname>Choong</surname><given-names>LY</given-names></name><name name-style="western"><surname>Lin</surname><given-names>Q</given-names></name><name name-style="western"><surname>So</surname><given-names>JB</given-names></name><etal/></person-group>. <article-title>Upregulation of plasma C9 protein in gastric cancer patients</article-title>. <source>Proteomics</source> (<year>2010</year>) <volume>10</volume>(<issue>18</issue>):<page-range>3210–21</page-range>. doi: <pub-id pub-id-type="doi">10.1002/pmic.201000127</pub-id><pub-id pub-id-type="pmcid">PMC3760195</pub-id><pub-id pub-id-type="pmid">20707004</pub-id></mixed-citation>
        </ref>
        <ref id="B68">
          <label>68</label>
          <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Joshi</surname><given-names>V</given-names></name><name name-style="western"><surname>Shah</surname><given-names>A</given-names></name><name name-style="western"><surname>Brown</surname><given-names>I</given-names></name><name name-style="western"><surname>Winterford</surname><given-names>C</given-names></name><name name-style="western"><surname>Hill</surname><given-names>M</given-names></name></person-group>. <article-title>Complement component C9 as a new biomarker for esophageal adenocarcinoma</article-title>. <source>J Clin Oncol</source> (<year>2017</year>) <volume>35</volume>(<issue>4_suppl</issue>):<page-range>19–9</page-range>. doi: <pub-id pub-id-type="doi">10.1200/JCO.2017.35.4_suppl.19</pub-id></mixed-citation>
        </ref>
        <ref id="B69">
          <label>69</label>
          <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>L</given-names></name><name name-style="western"><surname>Yang</surname><given-names>H</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Li</surname><given-names>XD</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>TT</given-names></name><name name-style="western"><surname>Lin</surname><given-names>SX</given-names></name><etal/></person-group>. <article-title>Hypoxia restrains the expression of complement component 9 in tumor-associated macrophages promoting non-small cell lung cancer progression</article-title>. <source>Cell Death Discov</source> (<year>2018</year>) <volume>4</volume>:<fpage>63</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41420-018-0064-3</pub-id><pub-id pub-id-type="pmid">29900010</pub-id><pub-id pub-id-type="pmcid">PMC5992192</pub-id></mixed-citation>
        </ref>
        <ref id="B70">
          <label>70</label>
          <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>GZ</given-names></name><name name-style="western"><surname>Deng</surname><given-names>JF</given-names></name><name name-style="western"><surname>Qi</surname><given-names>YZ</given-names></name><name name-style="western"><surname>Liu</surname><given-names>R</given-names></name><name name-style="western"><surname>Liu</surname><given-names>ZX</given-names></name></person-group>. <article-title>COLEC12 regulates apoptosis of osteosarcoma through toll-like receptor 4-activated inflammation</article-title>. <source>J Clin Lab Anal</source> (<year>2020</year>) <volume>34</volume>(<issue>11</issue>):<elocation-id>e23469</elocation-id>. doi: <pub-id pub-id-type="doi">10.1002/jcla.23469</pub-id><pub-id pub-id-type="pmid">32822099</pub-id><pub-id pub-id-type="pmcid">PMC7676208</pub-id></mixed-citation>
        </ref>
        <ref id="B71">
          <label>71</label>
          <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Espinal-Enríquez</surname><given-names>J</given-names></name><name name-style="western"><surname>Muñoz-Montero</surname><given-names>S</given-names></name><name name-style="western"><surname>Imaz-Rosshandler</surname><given-names>I</given-names></name><name name-style="western"><surname>Huerta-Verde</surname><given-names>A</given-names></name><name name-style="western"><surname>Mejía</surname><given-names>C</given-names></name></person-group>. <article-title>Genome-wide expression analysis suggests a crucial role of dysregulation of matrix metalloproteinases pathway in undifferentiated thyroid carcinoma</article-title>. <source>BMC Genomics</source> (<year>2015</year>) <volume>16</volume>(<issue>1</issue>):<fpage>207</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s12864-015-1372-0</pub-id><pub-id pub-id-type="pmid">25887408</pub-id><pub-id pub-id-type="pmcid">PMC4377021</pub-id></mixed-citation>
        </ref>
        <ref id="B72">
          <label>72</label>
          <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chang</surname><given-names>LL</given-names></name><name name-style="western"><surname>Hsu</surname><given-names>WH</given-names></name><name name-style="western"><surname>Kao</surname><given-names>MC</given-names></name><name name-style="western"><surname>Chou</surname><given-names>CC</given-names></name><name name-style="western"><surname>Lin</surname><given-names>CC</given-names></name><name name-style="western"><surname>Liu</surname><given-names>CJ</given-names></name><etal/></person-group>. <article-title>Stromal c-type lectin receptor COLEC12 integrates h. pylori, PGE2-EP2/4 axis and innate immunity in gastric diseases</article-title>. <source>Sci Rep</source> (<year>2018</year>) <volume>8</volume>(<issue>1</issue>):<fpage>3821</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41598-018-20957-2</pub-id><pub-id pub-id-type="pmid">29491476</pub-id><pub-id pub-id-type="pmcid">PMC5830506</pub-id></mixed-citation>
        </ref>
        <ref id="B73">
          <label>73</label>
          <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Q</given-names></name><name name-style="western"><surname>Shu</surname><given-names>Y</given-names></name></person-group>. <article-title>Role of solute carriers in response to anticancer drugs</article-title>. <source>Mol Cell Ther</source> (<year>2014</year>) <volume>2</volume>:<fpage>15</fpage>. doi: <pub-id pub-id-type="doi">10.1186/2052-8426-2-15</pub-id><pub-id pub-id-type="pmid">26056583</pub-id><pub-id pub-id-type="pmcid">PMC4452062</pub-id></mixed-citation>
        </ref>
        <ref id="B74">
          <label>74</label>
          <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sweet</surname><given-names>DH</given-names></name></person-group>. <article-title>Organic anion transporter (Slc22a) family members as mediators of toxicity</article-title>. <source>Toxicol Appl Pharmacol</source> (<year>2005</year>) <volume>204</volume>(<issue>3</issue>):<fpage>198</fpage>–<lpage>215</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.taap.2004.10.016</pub-id><pub-id pub-id-type="pmid">15845414</pub-id></mixed-citation>
        </ref>
        <ref id="B75">
          <label>75</label>
          <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hu</surname><given-names>S</given-names></name><name name-style="western"><surname>Leblanc</surname><given-names>AF</given-names></name><name name-style="western"><surname>Gibson</surname><given-names>AA</given-names></name><name name-style="western"><surname>Hong</surname><given-names>KW</given-names></name><name name-style="western"><surname>Kim</surname><given-names>JY</given-names></name><name name-style="western"><surname>Janke</surname><given-names>LJ</given-names></name><etal/></person-group>. <article-title>Identification of OAT1/OAT3 as contributors to cisplatin toxicity</article-title>. <source>Clin Transl Sci</source> (<year>2017</year>) <volume>10</volume>(<issue>5</issue>):<page-range>412–20</page-range>. doi: <pub-id pub-id-type="doi">10.1111/cts.12480</pub-id><pub-id pub-id-type="pmcid">PMC5593168</pub-id><pub-id pub-id-type="pmid">28689374</pub-id></mixed-citation>
        </ref>
        <ref id="B76">
          <label>76</label>
          <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sági</surname><given-names>JC</given-names></name><name name-style="western"><surname>Egyed</surname><given-names>B</given-names></name><name name-style="western"><surname>Kelemen</surname><given-names>A</given-names></name><name name-style="western"><surname>Kutszegi</surname><given-names>N</given-names></name><name name-style="western"><surname>Hegyi</surname><given-names>M</given-names></name><name name-style="western"><surname>Gézsi</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Possible roles of genetic variations in chemotherapy related cardiotoxicity in pediatric acute lymphoblastic leukemia and osteosarcoma</article-title>. <source>BMC Cancer</source> (<year>2018</year>) <volume>18</volume>(<issue>1</issue>):<fpage>704</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s12885-018-4629-6</pub-id><pub-id pub-id-type="pmid">29970035</pub-id><pub-id pub-id-type="pmcid">PMC6029426</pub-id></mixed-citation>
        </ref>
        <ref id="B77">
          <label>77</label>
          <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sutherland</surname><given-names>R</given-names></name><name name-style="western"><surname>Meeson</surname><given-names>A</given-names></name><name name-style="western"><surname>Lowes</surname><given-names>S</given-names></name></person-group>. <article-title>Solute transporters and malignancy: Establishing the role of uptake transporters in breast cancer and breast cancer metastasis</article-title>. <source>Cancer Metastasis Rev</source> (<year>2020</year>) <volume>39</volume>(<issue>3</issue>):<page-range>919–32</page-range>. doi: <pub-id pub-id-type="doi">10.1007/s10555-020-09879-6</pub-id><pub-id pub-id-type="pmcid">PMC7497311</pub-id><pub-id pub-id-type="pmid">32388639</pub-id></mixed-citation>
        </ref>
        <ref id="B78">
          <label>78</label>
          <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ortiz</surname><given-names>B</given-names></name><name name-style="western"><surname>White</surname><given-names>JR</given-names></name><name name-style="western"><surname>Wu</surname><given-names>WH</given-names></name><name name-style="western"><surname>Chan</surname><given-names>TA</given-names></name></person-group>. <article-title>Deletion of ptprd and Cdkn2a cooperate to accelerate tumorigenesis</article-title>. <source>Oncotarget</source> (<year>2014</year>) <volume>5</volume>(<issue>16</issue>):<page-range>6976–82</page-range>. doi: <pub-id pub-id-type="doi">10.18632/oncotarget.2106</pub-id><pub-id pub-id-type="pmcid">PMC4196177</pub-id><pub-id pub-id-type="pmid">25138050</pub-id></mixed-citation>
        </ref>
        <ref id="B79">
          <label>79</label>
          <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Veeriah</surname><given-names>S</given-names></name><name name-style="western"><surname>Brennan</surname><given-names>C</given-names></name><name name-style="western"><surname>Meng</surname><given-names>S</given-names></name><name name-style="western"><surname>Singh</surname><given-names>B</given-names></name><name name-style="western"><surname>Fagin</surname><given-names>JA</given-names></name><name name-style="western"><surname>Solit</surname><given-names>DB</given-names></name><etal/></person-group>. <article-title>The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers</article-title>. <source>Proc Natl Acad Sci USA</source> (<year>2009</year>) <volume>106</volume>(<issue>23</issue>):<page-range>9435–40</page-range>. doi: <pub-id pub-id-type="doi">10.1073/pnas.0900571106</pub-id><pub-id pub-id-type="pmcid">PMC2687998</pub-id><pub-id pub-id-type="pmid">19478061</pub-id></mixed-citation>
        </ref>
        <ref id="B80">
          <label>80</label>
          <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peyser</surname><given-names>ND</given-names></name><name name-style="western"><surname>Du</surname><given-names>Y</given-names></name><name name-style="western"><surname>Li</surname><given-names>H</given-names></name><name name-style="western"><surname>Lui</surname><given-names>V</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>X</given-names></name><name name-style="western"><surname>Chan</surname><given-names>TA</given-names></name><etal/></person-group>. <article-title>Loss-Of-Function PTPRD mutations lead to increased STAT3 activation and sensitivity to STAT3 inhibition in head and neck cancer</article-title>. <source>PloS One</source> (<year>2015</year>) <volume>10</volume>(<issue>8</issue>):<elocation-id>e0135750</elocation-id>. doi: <pub-id pub-id-type="doi">10.1371/journal.pone.0135750</pub-id><pub-id pub-id-type="pmid">26267899</pub-id><pub-id pub-id-type="pmcid">PMC4534317</pub-id></mixed-citation>
        </ref>
        <ref id="B81">
          <label>81</label>
          <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Holmström</surname><given-names>MO</given-names></name><name name-style="western"><surname>Martinenaite</surname><given-names>E</given-names></name><name name-style="western"><surname>Ahmad</surname><given-names>SM</given-names></name><name name-style="western"><surname>Met</surname><given-names>Ö</given-names></name><name name-style="western"><surname>Friese</surname><given-names>C</given-names></name><name name-style="western"><surname>Kjær</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>The calreticulin (CALR) exon 9 mutations are promising targets for cancer immune therapy</article-title>. <source>Leukemia</source> (<year>2018</year>) <volume>32</volume>(<issue>2</issue>):<page-range>429–37</page-range>. doi: <pub-id pub-id-type="doi">10.1038/leu.2017.214</pub-id><pub-id pub-id-type="pmid">28676668</pub-id></mixed-citation>
        </ref>
        <ref id="B82">
          <label>82</label>
          <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>P</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>L</given-names></name><name name-style="western"><surname>Loos</surname><given-names>F</given-names></name><name name-style="western"><surname>Marty</surname><given-names>C</given-names></name><name name-style="western"><surname>Xie</surname><given-names>W</given-names></name><name name-style="western"><surname>Martins</surname><given-names>I</given-names></name><etal/></person-group>. <article-title>Immunosuppression by mutated calreticulin released from malignant cells</article-title>. <source>Mol Cell</source> (<year>2020</year>) <volume>77</volume>(<issue>4</issue>):<fpage>748</fpage>–<lpage>760.e9</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.molcel.2019.11.004</pub-id><pub-id pub-id-type="pmid">31785928</pub-id></mixed-citation>
        </ref>
        <ref id="B83">
          <label>83</label>
          <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Miyamoto</surname><given-names>R</given-names></name><name name-style="western"><surname>Uzawa</surname><given-names>N</given-names></name><name name-style="western"><surname>Nagaoka</surname><given-names>S</given-names></name><name name-style="western"><surname>Hirata</surname><given-names>Y</given-names></name><name name-style="western"><surname>Amagasa</surname><given-names>T</given-names></name></person-group>. <article-title>Prognostic significance of cyclin D1 amplification and overexpression in oral squamous cell carcinomas</article-title>. <source>Oral Oncol</source> (<year>2003</year>) <volume>39</volume>(<issue>6</issue>):<page-range>610–8</page-range>. doi: <pub-id pub-id-type="doi">10.1016/S1368-8375(03)00048-4</pub-id><pub-id pub-id-type="pmid">12798405</pub-id></mixed-citation>
        </ref>
        <ref id="B84">
          <label>84</label>
          <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>J</given-names></name><name name-style="western"><surname>Yan</surname><given-names>J</given-names></name><name name-style="western"><surname>Guo</surname><given-names>Q</given-names></name><name name-style="western"><surname>Chi</surname><given-names>Z</given-names></name><name name-style="western"><surname>Tang</surname><given-names>B</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>B</given-names></name><etal/></person-group>. <article-title>Genetic aberrations in the CDK4 pathway are associated with innate resistance to PD-1 blockade in Chinese patients with non-cutaneous melanoma</article-title>. <source>Clin Cancer Res</source> (<year>2019</year>) <volume>25</volume>(<issue>21</issue>):<page-range>6511–23</page-range>. doi: <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-19-0475</pub-id><pub-id pub-id-type="pmid">31375512</pub-id></mixed-citation>
        </ref>
        <ref id="B85">
          <label>85</label>
          <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rinaldi</surname><given-names>J</given-names></name><name name-style="western"><surname>Sokol</surname><given-names>ES</given-names></name><name name-style="western"><surname>Hartmaier</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Trabucco</surname><given-names>SE</given-names></name><name name-style="western"><surname>Frampton</surname><given-names>GM</given-names></name><name name-style="western"><surname>Goldberg</surname><given-names>ME</given-names></name><etal/></person-group>. <article-title>The genomic landscape of metastatic breast cancer: Insights from 11,000 tumors</article-title>. <source>PloS One</source> (<year>2020</year>) <volume>15</volume>(<issue>5</issue>):<elocation-id>e0231999</elocation-id>. doi: <pub-id pub-id-type="doi">10.1371/journal.pone.0231999</pub-id><pub-id pub-id-type="pmid">32374727</pub-id><pub-id pub-id-type="pmcid">PMC7202592</pub-id></mixed-citation>
        </ref>
        <ref id="B86">
          <label>86</label>
          <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arao</surname><given-names>T</given-names></name><name name-style="western"><surname>Ueshima</surname><given-names>K</given-names></name><name name-style="western"><surname>Matsumoto</surname><given-names>K</given-names></name><name name-style="western"><surname>Nagai</surname><given-names>T</given-names></name><name name-style="western"><surname>Kimura</surname><given-names>H</given-names></name><name name-style="western"><surname>Hagiwara</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>FGF3/FGF4 amplification and multiple lung metastases in responders to sorafenib in hepatocellular carcinoma</article-title>. <source>Hepatology</source> (<year>2013</year>) <volume>57</volume>(<issue>4</issue>):<page-range>1407–15</page-range>. doi: <pub-id pub-id-type="doi">10.1002/hep.25956</pub-id><pub-id pub-id-type="pmid">22890726</pub-id></mixed-citation>
        </ref>
        <ref id="B87">
          <label>87</label>
          <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>R</given-names></name><name name-style="western"><surname>Choi</surname><given-names>BY</given-names></name><name name-style="western"><surname>Lee</surname><given-names>MH</given-names></name><name name-style="western"><surname>Bode</surname><given-names>AM</given-names></name><name name-style="western"><surname>Dong</surname><given-names>Z</given-names></name></person-group>. <article-title>Implications of genetic and epigenetic alterations of CDKN2A (P16(INK4a)) in cancer</article-title>. <source>EBioMedicine</source> (<year>2016</year>) <volume>8</volume>:<page-range>30–9</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.ebiom.2016.04.017</pub-id><pub-id pub-id-type="pmcid">PMC4919535</pub-id><pub-id pub-id-type="pmid">27428416</pub-id></mixed-citation>
        </ref>
        <ref id="B88">
          <label>88</label>
          <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kung</surname><given-names>C-P</given-names></name><name name-style="western"><surname>Weber</surname><given-names>JD</given-names></name></person-group>. <article-title>It’s getting complicated–a fresh look at P53-MDM2-ARF triangle in tumorigenesis and cancer therapy</article-title>. <source>Front Cell Dev Biol</source> (<year>2022</year>) <issue>10</issue>:<fpage>818744</fpage>.<pub-id pub-id-type="pmid">35155432</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fcell.2022.818744</pub-id><pub-id pub-id-type="pmcid">PMC8833255</pub-id></mixed-citation>
        </ref>
        <ref id="B89">
          <label>89</label>
          <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Minaei</surname><given-names>E</given-names></name><etal/></person-group>. <article-title>Cancer progression gene expression profiling identifies the urokinase plasminogen activator receptor as a biomarker of metastasis in cutaneous squamous cell carcinoma</article-title>. <source>Front Oncol</source> (<year>2022</year>) <volume>12</volume>:<elocation-id>835929</elocation-id>. doi: <pub-id pub-id-type="doi">10.3389/fonc.2022.835929</pub-id><pub-id pub-id-type="pmid">35480116</pub-id><pub-id pub-id-type="pmcid">PMC9035872</pub-id></mixed-citation>
        </ref>
        <ref id="B90">
          <label>90</label>
          <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Siegel</surname><given-names>PM</given-names></name><name name-style="western"><surname>Massagué</surname><given-names>J</given-names></name></person-group>. <article-title>Cytostatic and apoptotic actions of TGF-β in homeostasis and cancer</article-title>. <source>Nat Rev Cancer</source> (<year>2003</year>) <volume>3</volume>(<issue>11</issue>):<page-range>807–20</page-range>. doi: <pub-id pub-id-type="doi">10.1038/nrc1208</pub-id><pub-id pub-id-type="pmid">14557817</pub-id></mixed-citation>
        </ref>
        <ref id="B91">
          <label>91</label>
          <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Melisi</surname><given-names>D</given-names></name><name name-style="western"><surname>Garcia-Carbonero</surname><given-names>R</given-names></name><name name-style="western"><surname>Macarulla</surname><given-names>T</given-names></name><name name-style="western"><surname>Pezet</surname><given-names>D</given-names></name><name name-style="western"><surname>Deplanque</surname><given-names>G</given-names></name><name name-style="western"><surname>Fuchs</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer</article-title>. <source>Br J Cancer</source> (<year>2018</year>) <volume>119</volume>(<issue>10</issue>):<page-range>1208–14</page-range>. doi: <pub-id pub-id-type="doi">10.1038/s41416-018-0246-z</pub-id><pub-id pub-id-type="pmcid">PMC6251034</pub-id><pub-id pub-id-type="pmid">30318515</pub-id></mixed-citation>
        </ref>
        <ref id="B92">
          <label>92</label>
          <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>YJ</given-names></name><name name-style="western"><surname>Hwang</surname><given-names>JS</given-names></name><name name-style="western"><surname>Hong</surname><given-names>YB</given-names></name><name name-style="western"><surname>Bae</surname><given-names>I</given-names></name><name name-style="western"><surname>Seong</surname><given-names>Y-S</given-names></name></person-group>. <article-title>Transforming growth factor beta receptor I inhibitor sensitizes drug-resistant pancreatic cancer cells to gemcitabine</article-title>. <source>Anticancer Res</source> (<year>2012</year>) <volume>32</volume>(<issue>3</issue>):<fpage>799</fpage>–<lpage>806</lpage>.<pub-id pub-id-type="pmid">22399597</pub-id><pub-id pub-id-type="pmcid">PMC3508670</pub-id></mixed-citation>
        </ref>
        <ref id="B93">
          <label>93</label>
          <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Feng</surname><given-names>DD</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>P</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>YS</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>XJ</given-names></name><name name-style="western"><surname>Han</surname><given-names>BW</given-names></name><etal/></person-group>. <article-title>Down-regulated miR-331-5p and miR-27a are associated with chemotherapy resistance and relapse in leukaemia</article-title>. <source>J Cell Mol Med</source> (<year>2011</year>) <volume>15</volume>(<issue>10</issue>):<page-range>2164–75</page-range>. doi: <pub-id pub-id-type="doi">10.1111/j.1582-4934.2010.01213.x</pub-id><pub-id pub-id-type="pmcid">PMC4394226</pub-id><pub-id pub-id-type="pmid">21070600</pub-id></mixed-citation>
        </ref>
        <ref id="B94">
          <label>94</label>
          <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>D</given-names></name><name name-style="western"><surname>Sui</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>X</given-names></name></person-group>. <article-title>MiR-331-3p inhibits proliferation and promotes apoptosis by targeting HER2 through the PI3K/Akt and ERK1/2 pathways in colorectal cancer</article-title>. <source>Oncol Rep</source> (<year>2016</year>) <volume>35</volume>(<issue>2</issue>):<page-range>1075–82</page-range>. doi: <pub-id pub-id-type="doi">10.3892/or.2015.4450</pub-id><pub-id pub-id-type="pmid">26718987</pub-id></mixed-citation>
        </ref>
      </ref-list>
    </back>
  </article>
</pmc-articleset>
